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INTRODUCTION. DESIGNING A ‘FEMALE VIAGRA’ 
Technology is inherently political and its creation and execution “is an ongoing social process 
in which scientific knowledge, technological invention, and corporate profit reinforce each other 
in deeply entrenched patterns, patterns that bear the unmistakable stamp of political and 
economic power” (Winner, 1986, p. 27).  
 
In a 2007 lecture titled “The marketing of Female Sexual Dysfunction (FSD): 
Illuminating current issues in sexuality and public health,” activist Leonore Tiefer discusses the 
implications of the way our society studies female sexuality and sexual issues. Tiefer asks the 
audience to think about whether sexology, the scientific study of human sexuality, more closely 
resembles studies on digestion or studies on music and dance. Although sexuality is both a 
cultural and biological matter, sexology uses language that denotes “normal” and “healthy” 
behavior in a way that one would not ever expect to find in literature about music or dance. The 
emphasis on biological research to address social phenomena strengthens medical and expert 
power, often at the expense of socio-cultural research. The sexual norms embedded within 
interactions between the medical field and female sexuality work to standardize and regulate 
sexual behavior, expectations, and frustrations. In this thesis, I aim to explore how medical and 
pharmaceutical attempts to study and treat female sexual issues reinforce misconceptions of 
female sexuality and reproduce conventional social norms. The failure to interrogate the social 
construction and the role of context in the female sexual experience has hindered the 
development of a successful ‘female Viagra’. The introduction of Addyi, the first FDA-approved 
pharmaceutical treatment for Female Sexual Dysfunction, provides a backdrop for which to 
observe the implications of operating within the male-dominated paradigm of sexual 
dysfunction.  
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Through the medicalization of female sexuality, sexual issues become matters of health 
and disorder. A medical framework is adopted to understand a problem, and a medical 
intervention is used to treat it (Conrad, 2000). This privileges scientific power through directing 
efforts into finding ‘cures’ rather than investigating the complex interplay of socio-cultural, 
environmental, relational, and personal contexts that contribute to sexual experience. The 
classification of Female Sexual Dysfunction is an example of medicalization working to define 
normal and natural sexual behavior as informed by an essentialist framework. Sexual 
essentialism, the idea that sex is a biological, asocial drive, is constantly reproduced in the 
medical discourse on sexuality (Rubin, 2011). In perpetuating the idea of an innate “sex drive,” 
the implication is that a lack or absence of sexual desire is unhealthy. Standardizing sexuality as 
an inherent property of human identity resists the exploration of social forces that influence an 
individual’s sexual desire. Pharmaceuticals play an active role in perpetuating this resistance by 
prioritizing and legitimizing sexual medicine.  
Sexual essentialist discussion privileges certain bodies and sexualities and fails to 
acknowledge natural sexual variation. Human sexual response is conceptualized as a uniform, 
linear process culminating in orgasm, which creates a narrow barometer for sexual normalcy. 
This dominant notion upholds biological and physiological aspects of sexual response, but it is 
also necessary to understand how sex is shaped by and gives meaning to social forces. Anne 
Fausto-Sterling suggests the metaphor of the Russian nesting doll to illustrate both the process by 
which gender is materialized within the body and the process by which gendered knowledge 
about the body is simultaneously produced (Fausto-Sterling, 2000). The Russian doll represents 
the layers of sexuality and the sources of knowledge within them, whether relating to the 
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historical, cultural, social, psychological, individual, or cellular. What is important is not each 
layer in isolation, but rather the doll’s disassembling and reassembling process. Sexual medicine 
such as Addyi ignores all of the non-biological layers that contribute to human sexuality and 
thereby discourages a deeper, more comprehensive understanding of female desire. The 
shortcomings of Addyi will demonstrate the impossibility of finding a pharmaceutical “cure” for 
female sexual problems, as the complexity of the construction of female sexuality inherently 
prevents a psycho-pharmaceutical intervention to be as lucrative as the blockbuster Viagra.  
Addyi targets Hypoactive Sexual Desire Disorder (HSDD), a female sexual dysfunction 
that focuses on the absence or lack of sexual desire or fantasy. Coined in the 1970s, HSDD is 
part of a long history of female sexual disorders. The first chapter focuses on the historical 
context of Addyi’s development by exploring the evolution of female sexual disorders in 20th 
and 21st century America, as exemplified in the editions of the Diagnostic Statistical Manual 
(DSM). The framework of DSM revisions illustrates how the medical field grappled with female 
sexuality and upheld strict, heterosexual, and gendered norms through the gravitation towards a 
more clinical, biological understanding of sex. The DSM editions show how the addition of more 
specific criteria and subtypes in the classification of female sexual dysfunction functions not to 
avoid overdiagnosis, but rather to legitimize the disorder and expand its manifestations to 
potentially broaden the prevalence of those affected.  
The emergence of Viagra in 1998 was revolutionary in its influence on interactions 
between the medical field, the pharmaceutical industry, and the study of sexual issues. The 
quick-fix drug’s massive success inaugurated the “sexopharmaceutical era”, characterized by a 
new paradigm in sexual medicine which promoted drug intervention as the solution to sexual 
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issues (Tiefer, 2006). Viagra shaped the methods by which the pharmaceutical industry 
approached female sexual dysfunction, spurring immediate efforts to find a ‘female Viagra’. The 
second chapter dives into the “Viagra Phenomenon” to illustrate the drug’s role in Addyi’s 
design and the stark contrast in the development and FDA approval process between the two 
drugs. While Viagra was fast-tracked through the FDA approval process soon after its discovery, 
Addyi’s multiple rejections became the topic of widespread controversy primarily in the feminist 
community. I will unpack the positions and rhetoric of the competing feminist campaigns that 
sprouted up both for and against the drug’s approval to direct attention to both the lack of 
consensus and the prevalent social ambivalence towards female sexual issues.  
Chapter 3 describes Addyi’s timeline after FDA approval, focusing on the challenges 
faced in its introduction to the market. Addyi is situated at the intersection of corporate interest, 
sexuality, and feminism. I will explore the implications of the gendered messages embedded 
within its marketing, primarily employed by the CEO of Sprout Pharmaceuticals Cindy Eckert. 
Promotional messages frame Addyi as a tool for female empowerment, applying a corporate 
feminist framework to increase profit. The story of Addyi’s initial introduction to the market in 
2015 and its relaunch in 2018, spearheaded by Cindy Eckert’s very pink media presence, 
provides the backdrop for my analysis of the inability of the medical field to develop a successful 
‘female Viagra.’  
As low sexual desire is the most common presenting sexual complaint in women, female 
desire or lack thereof has been the focus of popular, clinical, and scholarly attention (Hayes et 
al., 2006). The concept of desire is central to HSDD classification, yet the lack of consensus on 
its varying definitions and models persists. While dominant frameworks for sexual response 
O’Bryan 6 
continue to focus on biology over context, to ignore variation in women’s relationship to their 
sexuality, and to equate male and female bodies, alternative models are gaining traction in the 
field. Chapter 4 provides an overview of one such model, the Dual Control Model (DCM), as it 
provides a more comprehensive approach to female sexual issues that centers women’s 
experiences. It challenges the way sexology and sexual medicine reduce and medicalize sexual 
issues through a reconceptualization of sexual normalcy. Looking at sexual behavior through the 
lense of the DCM gives insight into why the efforts to design a pharmaceutical solution to female 
sexual dysfunction have not proved successful, and why it is important to promote meaningful 
shifts in sex research.  
This thesis does not attempt to argue that this drug hasn’t helped certain women, that 
there are not biological underpinnings for low desire, or that Addyi is inherently bad. Rather it 
serves to illuminate what is ignored through prioritizing and marketing this drug as the solution 
to low female sexual desire. Addyi is said to empower women through providing the choice to 
regain control of their sexual lives and reclaim their pleasure. But is this drug truly the key to 
sexual empowerment? Is developing a female equivalent to Viagra a win for women, or does 
Addyi act as a continuation of the history of medicalizing female sexuality? 
I want to point out that my thesis explores the heterosexual matrix in which sexual 
medicine, namely Addyi, is created. I often use the terms “woman” and “female,” and “man” and 
“male” interchangeably. This is a reflection of the language used in discussions of sexual 
medicine occurring in medical and scientific literature, in the popular press, in the marketing of 
Addyi, and by Addyi resistors and users. I acknowledge the difference between sex and gender, 
and that not all individuals assigned female at birth identify as women and not all individuals 
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assigned male at birth identify as men. For the purpose of this thesis, I want to make it clear that 
my use of “woman” and “man” denote cisgendered individuals. When exploring female sexual 
desire, I am discussing women who were assigned female at birth, raised as girls, and identify as 
women. The research on sexual dysfunction experienced by genderqueer and transgender 
individuals is limited and not within the bounds of this thesis, therefore I did not extend the 
conclusions and observations regarding the medicalization of cisgender women’s low desire to 
this demographic. I hope to highlight in this thesis how the heteronormative, conventional 
models dominant in sexology operate under a limited understanding of sexuality and gender that 






















CHAPTER I. THE HISTORY OF THE DISORDER AND THE DRU​G 
 
“Nowadays, if a woman lacks the desire for sex, and is bothered by it, she could be diagnosed 
with a disorder of low libido. That’s just one of the four main disorders of female sexual 
dysfunction described in one of the leading manuals of diseases. The others include disorders of 
arousal, orgasm, and pain. As the evidence plainly shows, forces are fast-amassing to tell you, 
and your doctor, that close to one in every two women suffers from some form of this new 
medical condition.” (Mintzes & Moynihan, 2010, p. 2) 
  
Addyi came onto the scene in 2015 as the first pharmaceutical drug to address 
Hypoactive Sexual Desire Disorder (HSDD), but it emerged out of a long history of 
pathologizing female sexual issues. Female sexual disorders as we understand them should not 
be accepted as biological and certain, but rather as the product of interactions between the 
medical field and female sexuality. They are defined by certain behaviors and characteristics that 
are deemed outside of the realm of contemporary ideas of what a normal sexual response should 
be. The history of sexual dysfunction and disorder can be traced many centuries back, but for the 
purposes of understanding HSDD and the context for the emergence of Addyi, the focus of this 
chapter will be on clinical and medical descriptions of sexual disorders in North America over 
the course of the 20th and 21st centuries. The evolution of the Diagnostic and Statistical Manual 
(DSM) will form the foundation of the historical timeline, as this body of work is representative 
of the contemporary professional consensus on sexual disorders. This history is not necessarily a 
linear one; though the DSM is used in psychiatric practice, each edition has faced severe 
criticism and pushback. The American Psychiatric Association, medical practitioners, feminists 
and women’s organizations, the press, and the public have all wrestled with perceptions of 
sexuality and desire, with the disorders that exist to diagnose sexual issues, and with the 
treatments developed to address them. The negotiations encouraged by critiques of the DSM’s 
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classification of disorders contributed and continue to contribute to changes in the medical 
approach taken to address female sexual disorders. Through the revisions of the DSM and the 
prevailing models of sexual response, I aim to contextualize the significance of the discovery and 
approval of Addyi as it relates to the history of the medicalization of female sexuality. New 
models continue to evolve that challenge or alter dominant models of sexual response, but this 
chapter works to ground Addyi in the context in which it was developed.  
 
The Frigid Woman  
The female sexual disorder that dominated the medical field in the earlier half of the 20th 
century was frigidity, although the disorder dates back to at least the 13th century (Cryle & 
Moore, 2011). An exploration of frigidity illustrates the history of the medical field grappling 
with low desire. Here we will focus on the disorder as it relates to medical texts in North 
America in the 20th century, emerging in the medical language alongside growing anxiety about 
the changing and fragile role of women in society. Frigidity acted as an umbrella term to 
encompass a variety of situations relating to women’s unsatisfactory sexual functioning 
including vaginismus, orgasmic dysfunction, and a lack of sexual arousal or interest (Faulk, 
1973). Due to the long timeline of frigidity and the varied and changing meanings ascribed to it, 
it would be impossible to characterize it as a singular concept.  
Frigidity was given very loose and differing definitions over the course of the century; for 
some it was defined simply as a lack of satisfaction (Devensky, 1952), but for most it was 
defined in relation to a woman’s ability to orgasm (Caprio, 1953; Hitchsman & Bergler, 1936). 
American psychiatry, professionalized and medicalized early on in the 20th century, was 
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dominated by psychoanalysis towards the 1930s (Angel, 2010). This set the stage for Freud’s 
far-reaching writings on female sexuality which placed a great emphasis on a woman’s ability to 
orgasm with vaginal stimulation over clitorial stimulation (Wallen & Lloyd, 2011). Reviews and 
guidelines on the causes and treatment of frigidity perpetuated the idea that the vaginal orgasm 
was the key to sexual fulfillment and reinforced its definition as the inability to experience 
vaginal orgasm (Hitchsman & Bergler, 1936).  
As vaginal stimulation was associated with heterosexual intercourse, the “frigid woman” 
was defined in relation to her male partner. In the early 20th century there was a growing 
emphasis on the importance of sexual pleasure for maintaining a healthy marriage (Angel, 2010), 
and frigidity became seen as a barrier to being a good partner and wife (Caprio, 1953). A very 
popular 1959 study by New York psychiatrist Marie N. Robinson put out the bold claim that 
40% of married women suffer from frigidity, defined as the lack of a “true” orgasm (Robinson, 
1962). A woman deemed frigid was often seen as less feminine, possessing traits or behaviors 
associated with masculinity such as aggression (Caprio, 1953) and likely to rebel against 
traditional roles of womanhood through feminism and lesbianism (Ussher, 1997). In this way, 
the disorder worked to reinforce strict rules as to what constituted normal sex and uphold norms 
of femininity within heterosexual relationships simultaneously.  
The first edition of the APA’s Diagnostic and Statistical Manual (DSM) was published in 
1952, at a time when frigidity was still the clearest parallel to what would become the umbrella 
term Female Sexual Dysfunction (FSD). ​The existence of frigidity in the DSM-I suggests that it 
was very common in psychiatry in the U.S. at this time, but it was not universally accepted. One 
of the most influential individuals in the study of sexuality in the 20th century was Alfred 
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Kinsey, who published his landmark study ​ S​exual Behavior in the Human Female ​the year 
following the publication of the first DSM. Kinsey and his team at Indiana University 
interviewed more than 10,000 people and used the results to publish two editions, one regarding 
male sexuality and the other regarding female sexuality. Kinsey directly rejected frigidity as the 
universal term to describe a woman’s inability to function sexually, as the interviews revealed a 
great gap between the medical norms of the time and women’s self-reported sexual preferences 
and behaviors (Kinsey et al., 1998). He found that an assessment of female sexuality and 
pleasure based on clitorial stimulation and on vaginal stimulation produced very different results 
and argued for a better understanding of the biological sexual response. Kinsey’s work did not 
create a dramatic shift away from the myth of the vaginal orgasm nor a rejection of frigidity, as 
frigidity remained the most common female sexual disorder in the in the DSM-II published in 
the 1960s. However it did mark a slight and gradual gravitation towards broadening the 
parameters of normalcy and pleasure. 
 
Bringing sex into the lab 
The second edition of the DSM was published just two years after Masters and Johnson’s 
landmark study the ​Human Sexual Response​, but would not reflect its influence until the 
publication of the third edition. The Masters and Johnson study was a breakthrough in that it 
brought discussions of sexuality into a laboratory setting, pushing sexuality studies in a 
biological direction and replacing the term “frigidity” with the term “dysfunction” (Masters & 
Johnson, 1966). By filming hundreds of people engaging in sexual acts and measuring their 
physiological responses, their team created the human sexual response cycle consisting of 
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excitement, plateau, orgasm and resolution. The description of each stage focused mainly on the 
physiological mechanisms of the body’s response. For example, the excitement stage was 
characterized by self-lubrication, heavy breathing, erect nipples, blood swelling and increased 
sensitivity of the erectile tissues in the pelvis, vulva, and clitoris. The work produced by Kinsey 
and by Masters and Johnson illustrate a gravitation towards a more scientific, laboratory based 
measurement of sexuality that emphasizes the biological underpinnings of pleasure.  
The idea of a standardized, biological, linear sexual response reinforced strict criteria for 
what the medical and clinical fields considered a normal sexual response. The 1974 publication 
of the DSM-III relied heavily on the Masters and Johnson sexual response cycle, accompanying 
the APA’s more general categorical shift from ​psychoanalytical to biological psychiatry (Angel, 
2010). It featured the ​introduction of the category of Female Sexual Dysfunction (FSD), a new 
umbrella term encompassing all forms of sexual dysfunction in females. In this edition of the 
DSM-III, each phase of the sexual response cycle is explained in terms of gendered 
psychophysiologic changes and expressions of sexual behavior, and the diagnostic criteria for 
each specific dysfunction are only briefly laid out. It is important to note that while Masters and 
Johnson’s study was conducted within a medical framework, it did acknowledge sexuality and 
sexual pleasure as complex and influenced by social, cultural, and psychological contexts. 
However it was the biological factors of the sexual response cycle that were largely incorporated 
into the revisions of the DSM. These editions acknowledge several factors outside of biology 
that influence dysfunction; the predisposing factors mentioned for FSD include anxiety, high 
standards of sexual performance, sensitivity to rejection, negative attitudes towards sexuality, 
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and general psychopathology. However these more social or comprehensive factors still function 
to inform rather than negate diagnosis.  
Due to the focus on the biological aspect of sexual behavior, Masters and Johnson’s 
response cycle did not include a desire phase. The exclusion of this phase led to many criticisms 
that informed future DSM revisions, as desire would become increasingly central to the study of 
FSD (Goldey & Anders, 2012). Helen Singer Kaplan, a prominent American sex therapist, 
published ​Disorders of Sexual Desire​ in 1979 to discuss her conception of the human sexual 
response as a triphasic process with desire as the initial phase. She defined desire as ​a drive or 
appetite that “moves the individual to seek out, or become receptive to, sexual experiences” 
(Kaplan, 1979, p. 10). She also used the term ​Inhibited Sexual Desire (ISD) to distinguish desire 
disorder from the general FSD diagnosis. ​The influence of ​Kaplan’s definition, as well as the use 
of the term ISD, is visible in the updated 1980 and 1987 versions of the DSM-III. The four stages 
of the sexual response cycle that informed the classifications present in the later editions of the 
DSM-III’s were outlined as appetite, excitement, orgasm, and resolution. “Appetite” is defined 
by fantasies of and desire for sexual activity. ​The 1987 edition also featured the very first use of 
the term Hypoactive Sexual Desire Disorder (HSDD), defined as the “persistent or recurrently 
deficient or absent sexual fantasies and desire for sexual activity.” ​ HSDD replaced Kaplan’s 
ISD, as the term “inhibited” was not as clearly defined and had a psychoanalytic connotation 
(Brotto, 2010). The prevalence of HSDD was measured at 20% of the total population, affecting 
females at a much higher rate. In other words the DSM-III claims that 1 in 5 individuals “suffer” 
from the sexual dysfunction of low desire.  
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Kaplan’s work laid the groundwork for the increasing attention given to the prevalence of 
low desire in women and the growing body of research and literature produced in the early 21st 
century that interrogated the definition and potential measurements of desire. Low sexual desire 
was experienced by a considerable number of women, but the focus remained on how to 
diagnose and treat it rather than how to investigate the myriad of social, cultural, relational, and 
personal reasons influencing female desire. The later DSM-III editions’ enforcement of a 
biology-focused sexual response cycle reflect a lot of the work that came out of the 60s and 70s. 
This categorical shift from ​psychoanalytical to biological attempted to create more reliable, 
objective diagnostic criteria (Angel, 2010) ​ and paralleled the shift away from frigidity in that it 
aimed to be more specific, not more feminist (Tyler, 2011). 
 
The evolution of Hypoactive Sexual Desire Disorder 
The 1994 DSM-IV similarly defined sexual dysfunction in terms of the sexual response 
cycle, but included several new criteria that work to specify HSDD classification. Desire 
replaced appetite as a stage in the model present in the DSM-III; the terms appetite, desire, 
libido, interest, hunger, drive, and motivation are often used interchangeably in the professional 
literature discussing HSDD and sexual disorders more generally (Brotto, 2009). The text added 
categories that recognized sexual disorders’ relationship to substances and unrelated medical 
conditions, as well as acknowledged the influence of culture, ethnicity, religion, and society on 
sexual experiences and expectations. The description of HSDD in the DSM-IV is also long and 
detailed, divided into the sub groups of lifelong vs. acquired, generalized vs. situational, and due 
to psychological factors vs. due to combined factors.  
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One of the most important changes between the 1987 DSM-III and the 1994 DSM-IV is 
the inclusion of the criterion“marked distress” in the classification of HSDD. The prevalence of 
low desire accompanied by marked distress is considerably lower than the prevalence of low 
desire without accounting for marked distress (Oberg, et al., 2004; Dennerstein et al., 2006). In 
this way it worked to reduce overdiagnosis, as well as further clarify the parameters of the 
disorder and respect asexual identity. It wasn’t completely successful in this regard, as the 
DSM-IV still failed to acknowledge that distress can be experienced by asexual individuals in 
reaction to socio-cultural pressures related to sexuality (Brotto, 2010). The second added 
criterion of “interpersonal difficulty” was the result of suggestions that sexual difficulties and 
distress are often the result of the intricacies of partner dynamics and the relationship itself 
(Bancroft et al., 2003; Rosen et al., 2009; King et al., 2007). The criterion also attempted to 
avoid over-pathologization, as well as address the potential for “marked distress” to place 
excessive emphasis the individual.  
Both interpersonal difficulty and marked distress are intended to inform diagnosis, 
however as in every DSM, the DSM-IV left diagnosis up to the clinician’s judgement. This is 
due to the lack of data, the complexity of low desire, and the inability to reach a medical 
consensus on what constitutes low libido and how to quantify HSDD (Wood, et al., 2006). The 
context of the person’s life is supposed to be taken into account in clinical judgement through the 
addition of guiding subtypes, categories, and criteria. The argument can be made that the 
increased specificity of HSDD works to prevent inaccurate diagnosis or overdiagnosis. Yet the 
creation of subtypes doesn’t disqualify certain individuals from having HSDD or foster a more 
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comprehensive understanding of sexual complexity; instead it allows for flexibility and variation 
in the meaning and experience of HSDD in a way has the potential to broaden its prevalence.  
 
Defining desire  
The drastic changes seen in the contemporary DSM-V stemmed from the increasing 
focus on sexual desire and the many criticisms of the continued use of the sexual response cycle. 
Desire is central to HSDD, and yet there wasn’t a medical consensus on how to measure or 
define it. Kaplan had framed desire as drive for sex, similar to hunger or thirst. According to 
Lena Levine, a prominent American psychiatrist who studied sexual dysfunction and served on 
the DSM-IV subcommittee on gender identity disorders, desire is the ​‘‘sum of forces that incline 
us toward and away from sexual behavior” (Levine, 2002, p.39). She considers feelings of desire 
as central to one’s own identity, equating it to a voice in that it is a constant internal dialogue and 
to a barometer in that it measures and reflects many aspects of our lives. These definitions are in 
line with the strict, biological approach that places enormous weight on a person’s ability to feel 
desire. Others defined desire more inclusively as the subjective awareness of wanting to attain a 
sexual goal (Regan & Berscheid, 1999). ​Grappling with how to define desire accompanied 
efforts to create a model in the context of HSDD. Desire was thought of by some to be indicated 
specifically by an individual’s sexual behavior, while others focused on whether sexual desire 
should be considered as spontaneous or responsive.  
Pushback on Masters and Johnson’s lasting influence was seen through an increasing 
preference of the model of responsive desire, in which desire is seen as a non-spontaneous action 
in response to sexual stimuli, over the earlier notions of spontaneous desire (Everaerd & Laan, 
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1995; Basson, 2000). Studies have shown that some women engage in sexual activity without 
feeling desire (Beck, Bozman, & Qualtrough, 1991), women may or may not engage in sexual 
activity for reasons unrelated to desire (Cain et al., 2003), and sexual desire may be experienced 
in the absence of sexual activity (Brotto, et al., 2009). ​Rosemary Basson published an article in 
the ​Journal of Sex and Marital Therapy ​ in 2000 to address the issues with the use of a universal, 
linear cycle as a framework for classifying low sexual desire. In reframing the definition of 
HSDD to include unresponsiveness to sexual cues, Basson expanded receptivity to triggered as 
well as spontaneous desire (Basson, 2000). The sexual response cycle she proposed consists of 
neutrality, sexual stimulus, arousal, desire, emotional and physical satisfaction, and emotional 
intimacy. Through her rejection of the model of female sexual response used in previous editions 
of the DSM, HSDD is redefined as a combination of the absence of spontaneous desire and the 
absence of responsive desire to sexual triggers. She also notes the overlap that occurs between 
desire and arousal and the need for more specific subtypes of HSDD and FSAD.  
While varying definitions and models of desire circulated in medical and clinical 
literature, it became evident that desire was hard to measure and distinguish from arousal.  
The DSM-IV has separate classifications of the Hypoactive Sexual Desire Disorder and Female 
Sexual Arousal Disorder (FSAD). Many researchers felt that this differentiation was artificial 
(Ishak & Tobia, 2013; Basson, 2000; Brotto, 2010) and noted that a lack of desire does not 
necessarily prelude pleasure or satisfaction (Cain, et al., 2003). There were studies showing the 
disconnect between the female brain and female genitals, for example showing that a female may 
experience genital arousal when exposed to sexual stimuli despite a lack of any feeling of desire 
(Bancroft, 2010; Meana, 2010). The existing scientific evidence was generally unable to explain 
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female sexual desire, let alone concretely distinguish between desire and arousal. The growing 
body of information regarding this blurry distinction eventually led to the DSM-V’s merging of 
HSDD and FSAD into one disorder labeled Female Sexual Arousal and Interest Disorder 
(FSAID). 
It has clearly been difficult to form a medical and clinical consensus on female sexual 
issues and the dominant model of female sexual response in the DSM fails to acknowledge the 
complexity and variation in women’s sexuality. This lack of understanding is reflected in the 
discrepancy that exists between clinical perceptions of female desire and women’s perceptions of 
their own desire. In a UK study involving 401 women, the prevalence of sexual disorders 
determined by a tool commonly used in clinical diagnosis differed significantly from the 
prevalence of sexual disorders as reported by the women themselves (King et al., 2007). This 
suggests that clinical diagnosis for low desire disorders in women uses criteria that may be 
insufficient or irrelevant to women’s self-reporting of sexual problems. We will explore the 
efforts to address the need for a subject-centered, context-focused framework to understand 
female sexual issues more in depth in Chapter 4.  
 
The contemporary Diagnostic Statistical Manual  
Critics of the dominant model of sexual response called for a new classification of FSD 
that departed from the reductionist approach of previous editions of the DSM. The major 
changes in the contemporary DSM-V were the elimination of the human sexual response cycle 
and the merging of desire and arousal disorder into FSAID, defined as “a lack of, or significantly 
reduced, sexual interest/arousal.” These revisions are not necessarily the result of an effort to 
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create a more holistic, contextualized, feminist approach to sexual issues. Female HSDD 
continues to be used in clinical settings, by academic, medical, and popular literature, and in the 
marketing of sexual medicine. This is also true of the human sexual response cycle, which still 
represents the dominant model of sexual response. In the DSM-V, FSAID is featured alongside 
Female Orgasmic Disorder, Erectile Disorder, Delayed and Premature Ejaculation, Genito-Pelvic 
Pain/Penetration Disorder, and Male HSDD. It must manifest in at least three of the following: 
absent or reduced interest in or initiation of sexual activity, erotic thoughts or fantasies, 
excitement or pleasure during sexual activity, responsive interest or arousal to stimuli, or genital 
and nongenital sensations. The removal of the term “hypoactive” hypothetically worked to 
deemphasize sexual deficiency as well as broaden our understanding of sexual response beyond 
biology (Brotto, 2009). While the DSM-V still emphasizes clinical judgement for diagnoses due 
to lack of data, it mentions the importance of understanding the complex interplay between 
culture and biology, as reflected in the inclusion of partner factors, relationship factors, 
vulnerability factors, stressors, cultural and religious factors, and medical factors. In principle, 
there appears to be a greater effort to address the complex nature of sexuality and to move away 
from reductionist models that fail to include life context.  
 
Addressing the 43%  
In 1999, an article featured in the ​Journal of the American Medical Association ​gave 
birth to a statistic that would have a lasting legacy in the world of sexual dysfunction. The 
article, written by Edward Laumann from Chicago University, deemed sexual dysfunction an 
important public health concern affecting 43% of women between 18 and 59 years old 
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(Laumann, 1999). Since its publication, this journal has been cited thousands of times in both 
scholarly articles and the popular press. It prompted the forming of the International Society for 
the Study of Women’s Sexual Health (ISSWSH), a group of doctors nurses, sex therapists, and 
scientists, with the goal to drive further study of female sexual dysfunction (Schulte, 2015). 
Laumann’s “43%” came in the wake of the hugely successful marketing campaign of Viagra, 
and proved very important in justifying a market of unmet need for treatment of female desire 
disorders. Looking at the success of the Viagra campaign and the high prevalence rates of 
dysfunction being publicized, it became clear that a ‘female Viagra’ could prove necessary and 
lucrative. I will explore this “Viagra Phenomenon” in the following chapter to illustrate how the 
drug’s emergence affected the way the pharmaceutical industry would interact with sex and how 
it catalyzed considerable efforts to researching a female equivalent. 
The early 2000s featured several different approaches to address low desire in women 
after the FDA’s issue of draft guidelines for drug development to treat Female Sexual 
Dysfunction. These draft guidelines, intended to represent the FDA’s position on the 
development of FSD treatment, included “recommendations for sponsors on the design of 
clinical trials in support of new drug applications for the treatment of female sexual dysfunction” 
(Tiefer, 2001). It discussed trial populations, outcome assessment tools, endpoint measurements, 
and safety considerations (U.S. FDA, 2016). In the 2000 guidelines, the FDA stated that the 
primary endpoints should be based on the number of successful and satisfying sexual events 
(SSE), limited to “satisfactory sexual intercourse, sexual intercourse resulting in orgasm, oral sex 
resulting in orgasm, and partner-initiated or self-masturbation resulting in orgasm” (Tiefer, 
2001). The draft guidelines and prevailing understandings of female sexual issues perpetuate the 
O’Bryan 21 
historically orgasmocentric approach to female sexuality that defines success through orgasm 
and excludes social and interpersonal context.  
Female sexual dysfunction has been understood in a variety of ways, as reflected in the 
many revisions to the DSMs, the different disorders and dysfunctions that fall under the FSD 
umbrella, and the constant criticism surrounding each classification. There has been a consistent 
tension surrounding the addition of criteria for clarity in diagnosis of sexual disorders, while as it 
legitimizes the disease and encourages more careful diagnosis, it also creates a narrow model of 
sexual response and medicalizes behaviors that stray from the standard. Although the medical 
understanding of female sexuality has evolved in clarity, sensitivity, and complexity, it still rests 
on a simplified and symptomatic understanding of sexual response consistent with a reductionist 
point of view. Addyi is not a departure, but rather a continuation of the centuries-long evolution 
of female sexual disorders. Its development simultaneously legitimizes the medicalization of 
female sexuality and prompts important questions regarding societal norms and expectations of 











CHAPTER II. THE QUEST FOR THE LITTLE PINK PILL IN THE 
SEXUOPHARMACEUTICAL ERA 
 
“Sexuality must not be thought of as a kind of natural given which power tries to hold in check, 
or as an obscure domain which knowledge tries gradually to uncover. It is the name that can be 
given to a historical construct: not a furtive reality that is difficult to grasp, but a great surface 
network in which the stimulation of bodies, the intensification of pleasures, the incitement to 
discourse, the formation of special knowledges, the strengthening of controls and resistances, 
are linked to one another, in accordance with a few major strategies of knowledge and power.” 
(Foucault, 1990, p. 106)  
 
In a 2015 interview with Fortune Magazine entitled “Most Powerful Women: Next Gen,” 
Cindy Eckert wants to make it clear that Addyi is not the ‘female Viagra’ that it has been 
nicknamed by the popular press. She details the differences in the way the two drugs function 
and declares that the barometer of Addyi’s success should never be measured against an 
on-demand drug for men, but rather on the fact that with access to Addyi, women with a medical 
disorder have the choice to make their own sexual health decisions. According to Eckert, 
Addyi’s comparison with Viagra should only go so far as to say it will be as revolutionary for 
female sexual health as Viagra was for male sexual health. While the mechanisms of Addyi and 
Viagra are drastically different, Viagra focusing on a blood flow issue and Addyi targeting the 
brain, a lot can be learned from looking at the story of Viagra in relation to Addyi. Its emergence 
in 1998 was a huge success and directly spurred the race to find a female equivalent. Studying its 
impact on Addyi provides an illustration of the growing phenomenon of corporate interests to 
invest in the medicalization of sexuality in the sexuopharmaceutical era (Tiefer, 2006) and 
allows us to begin to understand the difficulties confronted in the quest for the little pink pill, 
despite many efforts in research and development. It also sets the stage to interrogate how the 
feminist community was conflicted and divided in conversations surrounding Addyi’s approval. 
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Addyi is shrouded in ambiguity and ambivalence; the lack of medical, social, and feminist 
consensus on female desire complicates its position in contrast to its male counterpart.  
 
The Viagra phenomenon 
“Viagra, an ED pill packaged as a male enhancement drug, represents medicalized and 
commodified masculinity, reinforcing ‘normal’ masculinity on both individual and social 
levels. At the center of this feedback loop is the embodied man, who must come to terms 
with the ‘clinical gaze’ that represents medical social control as well as the potential for 
empowerment and, by association, self-control that Viagra appears to symbolize in our 
postmodern age.”(Rosenfeld & Faircloth, 2006, p. 22) 
 
Viagra quickly became a blockbuster drug, a term designated for drugs that accumulate at 
least $1 billion in annual sales (Rosen, 2005). Like Addyi, it too was discovered accidentally; a 
developing treatment for Angina produced blood flow to the penis instead of the heart, resulting 
in the “happy accident” that would become Viagra. Although there were concerns voiced in the 
media for the pill’s potential to be abused or used recreationally, this posed only a brief 
interruption in its development (Loe, 2004). Viagra was fast-tracked through the FDA approval 
process without any input from external experts or non-governmental expert committees (Tiefer, 
2001) and approved in March of 1998, since then bringing in tens of billions in revenues 
(Mukherjee, 2018). The late 20th century alignment of pharmaceutical marketing, government 
policies, society’s growing interest in sex and pills, and the success of Viagra is coined as the 
“Viagra phenomenon” by sexologist, clinical psychologist, and anti-Addyi activist Leonore 
Tiefer (Tiefer, 2006). Tiefer was very interested in the implications of the Viagra phenomenon 
for sexology, and has used the concept to illustrate how the pharmaceutical industry’s 
enforcement of the idea that complex sexual problems are medical conditions and the reduction 
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of sexuality to its biological mechanisms. In the case of Viagra, erectile dysfunction positions the 
“penis as the patient” (ibid., p. 285).  
Viagra’s immediate and impressive sales have been attributed to three main things; 
defining erectile issues as a medical dysfunction, widening the audience of those affected, and 
selling the drug as a fail-proof solution (Moynihan & Mitzes, 2010). Although the interactions 
between female sexuality and medicine are unique, the gravitation towards a clinical, biological, 
medicalized approach to sex in the later 20th century applied to male sexuality as well. “Erectile 
dysfunction” (ED) was coined to replace the previous term “impotence” 6 years before the 
approval of Pfizer’s Viagra (ibid.). This re-labeling was in line with the biological understanding 
of sex epitomized in the writings of Masters and Johnson and Kinsey; ED was now understood 
as a biogenic rather than psychogenic problem. The primary criteria in the DSM-V for erectile 
disorder is that in approximately 75% to 100% of sexual events, an individual experiences 
marked difficulty in obtaining or maintaining an erection, or experiences a decrease in erectile 
rigidity. A diagnosis can be made even if the erectile issues are of mild severity.  
Similarly to the DSM’s presentation of HSDD, the factors relating to partners, culture, 
religion, self-esteem, and psychiatric comorbidity are mentioned, but only in their influence on 
the presentation of ED symptoms rather than as factors that might prevent a medical diagnosis. 
ED diagnosis centers the biological sexual response of the penis, and therefore it leaves out the 
social context of relationships, emotions, well-being, upbringing, and attitude towards sex (ibid.). 
Ericka Johnson, a researcher and professor who studied the presentation of masculinity on 
Pfizer’s Viagra website in Sweden, observed trends in the discussion of ED in scholarly articles 
in a Swedish medical journal from 8 years prior to Viagra’s approval through 8 years after 
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(Johnson, 2008). In the years leading up to 1998, the papers stressed the evaluation of biological 
factors, emotional well-being and interpersonal relationships in diagnosing ED. After Viagra 
emerged, the discussion was disease-centric and focused on the physical factors. The 
understanding of the patient and of sex narrowed, and the diversity of the authors also narrowed 
to primarily include urologists. The shift illustrated in Johnson’s study accounts for the 
progression in the medicalization of sexual problems as exemplified in defining erectile issues as 
a medical dysfunction.  
Viagra was fast-track FDA approved in 6 months only 2 years after it was patented. In 
order to bolster sales, the audience of those affected by the dysfunction was widened to include 
as many potential consumers as possible. Edward Laumann’s 1999 article on sexual dysfunction 
which gave birth to the 43% statistic for FSD also estimated the prevalence of ED at a range of 
10 million to 50% of the US male population (Laumann, 1999). While initially ED was mainly 
associated with older men experiencing dysfunction attributed to medical problems such as 
prostate cancer or diabetes, Pfizer broadened the market and in turn allowed for recreational use 
by including any man who experienced issues getting an erection, keeping one, or who just 
wanted to enhance his performance (Conrad & Leiter, 2004). The expectations of erectile 
functioning became more demanding “so that most penises would fail or falter at some point or 
other and so that the incidence of ‘impotence,’ or at least ‘erectile insecurity,’ would escalate” 
(Tiefer, 2006, p. 279). It was a fail-proof solution and was advertised as such. Pfizer employed 
direct-to-consumer advertising (DTCA), which steps outside of the realm of the doctor’s office 
to position patients as consumers in the market of pharmaceutical drugs (Conrad & Leiter, 2008). 
It was in 1997 that the FDA released guidelines for TV drug advertising that allowed for certain 
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prescription DTCA, feared by some to potentially contribute to the medicalization of the human 
experience (Bonaccorso & Sturchio, 2002). By 1999, Americans on average saw 9 prescription 
drug advertisements a day on TV (Conrad & Leiter, 2008). Broadcast DTCA grew from $55 
million in 1991 to $4.2 billion in 2005 (USGAO, 2006) with 330% growth from 1996 to 2005 
(Donohue et al., 2007). A competitive market was developing in the early 2000s for erectile 
dysfunction with similar treatments such as Levitra and Cialis. Famous male celebrities, such as 
race car driver Mark Martin and former NFL football player and coach Mike Ditka, addressed 
the “millions” of men with erectile dysfunction in hyper-masculine advertisements. By 2004 
drug companies spent $382 million in advertising for ED drugs in the U.S. and had sales of $1.36 
billion (Snowbeck, 2005). The public image of Viagra as depicted in its advertisements targeted 
the demographic of middle-aged and older, white, middle and upper-class, heterosexual men. 
However the population of users extended beyond Pfizer’s defined target group to include men 
of different ages, sexual preferences, socioeconomic levels, racial groups, and even women (Loe, 
2004). Viagra’s position as a quick-fix drug emerged out of and reinforced heteronormative 
stereotypes and expectations of masculinity while simultaneously becoming a widely used 
everyday man’s drug. Viagra is a very familiar example of “economic forces and social 
meanings” generating the making of a disease (Kukla, 2016, p. 185). The pharmaceutical 
industry framed sexual problems regarding erection as a medical condition, one that potentially 





Early attempts at addressing low female sexual desire  
Addyi was FDA approved as the first drug to treat Female Sexual Dysfunction 17 years 
after the FDA approval of Viagra. Cindy Eckert argued that the difference between the drugs’ 
timelines is the result of sexism within the medical field and the FDA, however the quest for the 
little pink pill began immediately after Viagra’s success. Paralleling the path of Viagra, low 
desire was categorized as a dysfunction and a large potential market of unmet need was 
established. There were many early attempts to design a female version of Viagra -creams, 
patches, pills, clitoral therapy devices- and there wasn’t a lack in funding or interest to conduct 
research. Yet despite all of this attention, the pharmaceutical industry was unable to design a 
successful ‘female Viagra’. The early attempts have been criticized for relying on the human 
sexual response cycle and reinforcing sexual scripts that uphold normative assumptions of 
femininity and sexuality (Fishman & Mamo, 2001).  
Following Viagra’s launch, there was a race to develop indices and measuring tools to 
better understand FSD and inform drug development, such as the ​female sexual function index 
and the decreased sexual desire screener (Lodise, 2017) ​. As early as 1999 a cream was patented 
that was said to induce multiple female orgasms and eliminate the need for foreplay, although 
with limited success (Riordan, 1999). A few other non-pharmaceutical approaches were 
approved by the FDA, such as a clitoral therapy device that uses suction to increase blood flow 
to the clitoris and in turn aids in vaginal lubrication and clitorial sensation. The EROS device, 
sold with a prescription at just under $400, was shown to be relatively effective in improving 
symptoms, however the studies were small, short, and lacking long-term follow ups (Wilson, et 
al., 2001). ​Research on the ability of Viagra to treat FSD was also investigated by Pfizer in the 
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early 2000s due to Viagra’s huge success at addressing male sexual dysfunction, however it 
concluded that female sexuality was more complicated than anticipated. The l ​arge majority of 
women with low desire didn’t respond to Viagra in the same way as men did (Kohn, 2008). The 
drug caused blood flow to female genitals but did not necessarily lead to increased sexual desire, 
a phenomenon known as “arousal nonconcordance”. While for males there is a 50% overlap 
between blood flow and the feeling of being “turned on,” this overlap is reduced to 10% for 
females (Nagoski, 2015). This gendered difference is rooted in the importance of context for the 
female sexual response, which will be explored more in Chapter 4. Pfizer decided to stop their 
studies of Viagra’s effect on low female sexual desire after 8 years of research. HSDD ​was ​ being 
heavily researched since the time of Viagra, but a simple quick-fix, fail-proof solution was 
proving difficult to find.  
Even though it took 17 years for a drug that specifically targets FSD to be approved, 
prescriptions were being written for women long before. Between 2006 and 2007, 2 million 
testosterone prescriptions were written for women who were diagnosed with HSDD (Kwan, 
2008; Snabes & Simes, 2009). Procter & Gamble applied to the FDA in 2004 for the Intrinsa 
testosterone patch for women, which was the first medicine ever to be brought to the FDA for 
female sexual dysfunction. Its target audience was women who suffer from HSDD, the “disease 
of low libido” as the P&G team called it at the FDA hearing, or who have had a hysterectomy 
(Moynihan & Mitzes, 2010). The patch “delivers small transdermal pulses of the sex hormone 
thought to play a crucial if poorly understood role in male and female libido alike” (Angier, 
2007). A large survey conducted by Procter & Gamble found that of 30 million women who are 
naturally menopausal, 3 million are distressed by their lack of sexual desire (New View 
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Campaign, 2014). This gave rise to the statistic that 1 in 10 women have HSDD. Procter & 
Gamble hired a global public relations team and advertisement agency, sponsored meetings and 
debates on the topic, consulted sex experts, funded an education package for doctors about 
HSDD, and put aside $100 million for advertising prior to their FDA hearing (Moynihan & 
Mitzes, 2010). At the hearing, the company spokesperson Mary Johnson claimed there was a 
“large unmet need” for a treatment for FSD, and highlighted the fact that their proposal received 
priority review status from the FDA. Despite this attention, research, and funding, the FDA voted 
unanimously against approval due to doubts regarding the adequacy of the scientific data in 
terms of efficacy, the powerful placebo, the side effects, and the long term health risks. The 
efficacy was measured at one additional sexually satisfying event (SSE) per month when 
compared to placebo, with a “sexual event” defined here as any sexual behavior that does or does 
not involve an orgasm (EMA, 2010 & Spark, 2005). One study published in the ​Drugs and 
Therapeutics Bulletin ​ warned that common side-effects of the Intrinsa patch included “acne, 
excessive hair growth, breast pain, weight gain, insomnia, voice deepening and migraine” 
including unknown long term effects such as increased risk of breast cancer (Moynihan & 
Mitzes, 2010, p. 165). This first attempt at an FDA approved drug proved that the search was 
going to be very different from the story of Viagra.  
 
The discovery of Boehringer’s little pink pill 
In 2006, two years after the rejection of the Intrinsa testosterone patch, the German 
pharmaceutical company Boehringer Ingelheim International discovered flibanserin, also known 
as Addyi. The drug, originally designed as an antidepressant, was found to have the side effect of 
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increasing female sexual desire. Flibanserin is a psychotropic medicine and functions by 
targeting the part of the brain linked to sexual motivation, although the exact mechanisms by 
which it does so are not completely understood. According to the director of Women’s 
Healthcare of Princeton, Maria Sophocles, it is a “once-daily, oral, mixed serotonin agonist and 
antagonist” (Kunzmann, 2019). In a press release, Boehringer used Procter & Gamble’s “1 in 
10” statistic to claim the existence of a serious unmet medical need of an HSDD treatment and 
began conducting clinical trials (Meyer-Kleinmann, 2008).  
Boehringer and several other drug companies organized and sponsored a conference on 
sexual medicine at the grand lecture theatre of Palais des Congres in 2009. It coincided with the 
company finishing up their trials before applying to FDA, so their excitement surrounding the 
drug’s supposed success and efficacy was evident (Moynihan & Mitzes, 2010). Anita Clayton, a 
spokesperson with financial ties to some of the world’s leading drug companies like Pfizer and 
Boehringer, gave a noteworthy talk on the concept of the “powerful placebo,” stating it was the 
major reason for Intrinsa’s rejection by FDA. According to her and other researchers in sexual 
health, the effect of the powerful placebo explained why there was still no sexual drug that 
showed a meaningful benefit for women despite the research and money directed at this assumed 
large market. Clayton claimed that the powerful placebo plays a problematic role in the logistics 
of FDA approval, and advised them to de-emphasize the placebo effect to ease the approval 
process (ibid.). Also in attendance was Lori Brotto, a psychologist and sex researcher whose 
work regarding female desire and arousal influenced the DSM revisions of HSDD (Brotto, 
2010). Supported by Leonore Tiefer, Brotto talked about how the discussions around FSD and 
HSDD ignore the role of relationships, focus too much on the individual, and inflate the 
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prevalence estimates (Moynihan & Mitzes, 2010). The Paris conference was the site of 
uncertainty and conflict surrounding sexual medicine.  
After the completion of Phase III clinical trials for flibanserin, Boehringer submitted their 
application to the FDA. The five Phase III and two extension studies are collectively known as 
the BOUQUET studies, each one named after a type of flower; Dahlia, Violet, Daisy, Orchid, 
Rose, Sunflower, and Magnolia (Clayton et al., 2010). In order to qualify for these trials, 
participants had to be women in stable, communicative, monogamous, heterosexual relationships 
of one or more years and had to have a certain distress score on the decreased sexual desire 
screener to indicate they could be diagnosed with HSDD. Both the highly feminized trial names 
and the narrow participant requirements raise questions about the politics embedded in this drug 
development. Whose low desire is being prioritized? The Phase III trials had coprimary 
endpoints of both a change in SSE/month and in the sexual desire score recorded by participants 
in an electronic diary, the eDiary. Although the requirements for participation were very strict, 
the criteria for what constituted a sexual event were broadened to include sexual intercourse, oral 
sex, masturbation, and genital stimulation by a partner. These primary and secondary endpoints 
are informed by FDA draft guidance, as there isn’t a clear standardized roadmap for approval of 
a medicine to treat HSDD due to “the difficulties in measuring a complex cognitive experience 
such as sexual desire” (ibid., p. 644). It is not surprising that in many of the trials there was no 
notable difference between the placebo and flibanserin, however with certain dosage and time of 
ingestion the results were said to have a positive risk-benefit ratio. This was not enough for 
approval; after reviewing the trial data the FDA rejected the drug in June of 2010 based on its 
lack of effect on daily sexual desire and the concern regarding potential adverse effects (Joffe et 
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al., 2016). Due to the extensive research required to gain approval, Boehringer pulled the plug on 
flibanserin (Grogan, 2010). Despite the company’s efforts to promote HSDD through hiring 
professionals and celebrities, highly incentivizing leading sex experts to attend conferences, and 
conducting several drug trials, the U.S. was still without an approved treatment to target FSD.  
 
Sprout’s fight to “even the score” through FDA approval  
The Sexual Medicine Society’s 2010 meeting proved to be an important moment in the 
timeline of flibanserin. The meeting was attended by Cindy Eckert, the head of the U.S. based 
pharmaceutical company Sprout that sold implantable testosterone for men ( ​Pollack & Bray, 
2015). ​ ​Dr. Irwin Goldstein was also in attendance, considered a “modern-day Masters and 
Johnson” by Eckert, and an important figure in the development of Viagra and Boehringer’s 
efforts to get flibanserin approved. Dr. Goldstein stopped Eckert at the meeting to show her a 
video he recorded of the moment in which he notified Boehringer’s clinical trial participants that 
flibanserin had been rejected by the FDA. After seeing these women shake their heads, cry, and 
tell him what the drug would mean for their relationships, Eckert decided to sell off her 
profitable business in men to take on sexual medicine for women, requiring her to “strap on her 
pink boxing gloves and start throwing punches” (MacKenzie, 2018).  
It was 2011 when Sprout pharmaceuticals entered the quest for a ‘female Viagra’. When 
the company applied to the FDA for the first time in 2013, the global ED market had just reached 
$4.3 billion (Schulte, 2015). ​Viagra, Cialis, Stendra/Spedra, Levitra, Staxyn, MUSE, Zydena, 
Mvix and Helleva all existed as FDA approved treatments for male sexual dysfunction. However 
Sprout’s initial submission for a female equivalent was rejected off the bat due to the high risk 
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and modest benefit; the FDA requested additional studies to be conducted regarding interactions 
with other drugs, the fatigue side effect, and the alcohol interactions (ibid.). Eckert voiced her 
disappointment, stating that the existing data warranted approval, but since a low value was 
assigned to the benefit of increased sexual desire, the risk undoubtedly would outweigh it. In the 
case of Addyi, Eckert claimed the lack of empathy for women’s experience affected the benefit 
value. On the other hand, ​Barbara Mintzes, co-author of ​Sex, Lies and Pharmaceuticals ​ and 
professor at the University of British Columbia, stated “it is hard to see what is sexist about the 
national drug regulatory agency refusing to approve a drug that was ineffective” (Thacker, 
2014). ​This tension between interpreting the FDA’s consistent rejection as a reflection of its 
institutional sexism or as a careful and accurate analysis of the data presented was prevalent in 
discussions within the feminist community. As Sprout continued to gather research and data in 
preparation for a second submission, several women’s health organizations became involved in 
the controversy surrounding Addyi’s 2013 rejection. Differences in ideologies and attitudes 
toward sexual medicine caused a rift in the position of women’s groups. While some such as the 
New View Campaign urged the FDA to continue to reject the drug, others such as the prominent 
Even the Score campaign organized to encourage approval.  
In 2014 the FDA announced 20 meetings on “patient-focused drug development” to bring 
together clinicians and patients to discuss diseases that remain without approved treatments (U.S. 
FDA, 2013). Usually these patient-focused meetings are reserved for life-threatening, incurable 
diseases, however this time female sexual dysfunction was added to the list (Block & Canner, 
2016). The FSD drug hearing was a two-day event in Maryland attended by pharmaceutical 
companies, company allies, and women recruited and paid to testify about their experience with 
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low desire (New View Campaign, 2014). It was also attended by organizers of the Working 
Group on A New View of Women’s Sexual Problems, or simply the New View campaign, an 
international collaboration of clinicians and social scientists created by Leonore Tiefer. The 
group lobbies against drugs targeting FSD and proposes a complex, woman-centered definition 
and approach to sexual problems in order to avoid the reduction of sexuality to biological 
mechanisms (Tiefer & Beres, 2005). They were in attendance with the goal of investigating and 
unearthing the research and promotional techniques of pharmaceutical companies that are biased 
towards profit rather than individual pleasure. The New View participated in the FDA hearing of 
Intrinsa in 2004, the FDA hearing of flibanserin in 2010, and the FDA’s hearing on drug 
development for FSD in 2014. Through speaking out, providing data and petitions, and centering 
women’s experiences, the group has fought actively against flibanserin and the medicalization of 
female sexuality.  
At the 2014 hearing, the New View commended the FDA for its continued pro-women 
rejection of the unsafe and ineffective drugs developed to treat FSD. They raised concerns 
regarding the history of the medicalization of sexuality, the ambiguous drug safety and efficacy, 
the rhetoric used to promote sexual medicine as the cure to a disease, and the appropriation of 
feminist rhetoric in the pro-Addyi argument. They also presented the FDA with petitions they 
had collected as well as a “juicy bibliography of 27 counter-narratives to the narrow and 
unenlightened (not to mention inaccurate and self-serving) view of women's sexuality and sexual 
problems offered by the pharmaceutical industry” (New View Campaign, 2014). This included a 
range of studies regarding female sexuality; a study focusing on the lack of physician knowledge 
of the complexity of female sexual disorders (Bachmann, 2006); national survey results 
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suggesting the predictors of sexual distress from women’s perspectives were not in line with 
DSM criteria (Bancroft et al, 2003); a Swedish study indicating that 6 months post-birth parents 
often show mutual discontent with their sexual relationship but happiness in the overall 
relationship (Ahlborg et al., 2005). The New View Campaign actively voiced their concern with 
the pro-Addyi Even the Score campaign, described by the New View as a “flagrant marketing 
tactic disguised as a pro-woman initiative” (New View Campaign, 2014). Similarly, others have 
called the campaign “classic faux-advocacy” and claimed it “emotionally blackmailed” the FDA 
into approval (Cassels, 2015). Even the Score’s ties to corporate interests brought about a lot of 
controversy and attention, especially as their campaign was credited as very influential in 
Addyi’s FDA approval.  
Even the Score was a coalition of nonprofit and for-profit organizations formed in June of 
2014 to urge the FDA to accept Addyi, framed as a grassroots effort to expose gender bias in the 
FDA. The leaders of the group said that it evolved out of discussions among existing women’s 
groups (Tavernise & Pollack, 2015) and was created “to serve as a voice for American women 
who believe that it’s time to level the playing field when it comes to the treatment of women’s 
sexual dysfunction” (Hogenmiller et al., 2017). In early 2014 a group of women’s organizations 
including the National Organization for Women (NOW) and the National Council of Women’s 
Organizations (NCWO) met with the director of the FDA Center for Drug Evaluation and 
Research who had also served as assistant commissioner for women’s health at FDA (ibid.). 
They invited Anita Clayton, the psychiatrist with financial ties to Boehringer that gave a 
noteworthy talk on the concept of the powerful placebo in 2004. Clayton, at this time a paid 
consultant of Sprout Pharmaceuticals, suggested the women organize a campaign to lobby 
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against the FDA. In a ​Huffington Post​ column, Clayton claimed the FDA’s rejection of Addyi 
came out of a male-centric approach to FSD and urged them “overcome the problem of 
institutionalized sexism- unconscious and perhaps unintended, but damaging nonetheless” 
(Clayton, 2014). A public relations company was approached and the campaign managed to 
garner support from much of the nonprofit women’s health community in Washington DC and 
included organizations such as the American College of Nurse Midwives, the National 
Association of Nurse Practitioners in Women’s Health, and the Black Women’s Health 
Imperative (Tavernise & Pollack, 2015). However, board members at several of the participating 
organizations such as the American College of Nurse Midwives, the Jewish Women 
International, and the Black Women’s Health Imperative said they were unaware of their 
involvement in the Addyi campaign and thought the campaign was a “sexual health equity” 
campaign rather than a campaign in support of sexual medicine. One board member commented, 
“to me, it really looks like we and probably some of those other organizations were tricked into 
being part of something that we were never intending to endorse” (Block & Canner, 2016). 
Many other women’s groups refused to support Even the Score, such as the National Women’s 
Health Network and Our Bodies Ourselves. While its support aided in its visibility and power, a 
considerable amount of that support was misled and misinformed. 
 
A rift in the feminist community 
The ideologies of the Even the Score campaign and the New View campaign are at odds 
with each other; although both claim to have the mission of female sexual empowerment, the 
method by which to achieve this empowerment is conceptualized differently between the two. 
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Even the Score, and more generally those in favor of sexual medicine, view Addyi as a tool for 
women to reclaim control over their sexual lives. The New View believes true agency involves 
promoting a more holistic, women-centered, inclusive approach that acknowledges social, 
relational, and cultural contexts. This tension is representative of a several-decade-old 
ambivalence within the feminist community towards female sexuality. 
The conversation surrounding sexual medicine after Viagra’s introduction is reminiscent 
of feminist discussions in early stages of the contemporary feminist movement. The sexual 
liberation movement of the 1960s centered on the idea that women’s liberation would be 
achieved through a shift in sexual attitudes and behaviors. Feminist thinkers urged women to be 
sexual agents, enjoy sexual pleasure, experiment with new sexual encounters, and “be sexually 
free” (hooks, 1984, p. 148). Sexual liberation was a means by which to resist the patriarchal, 
conservative norms imposed on women’s sexual lives, and worked to revise the framework of 
sex in America through encouraging sexual behavior outside of heterosexual marriage (Fahs, 
2011). Though challenging the repression of female sexuality, the movement did not deconstruct 
the gendered power relations present within the sexual sphere; society is more responsive to 
feminist demands that are non threatening and work to maintain the status quo such as engaging 
in more or better sexual activity (hooks, 1984). The movement failed to address the stigma 
connected to asexuality or low libido. Being sexual was still natural, while not being sexual was 
unnatural. The same ideology is expressed in contemporary mass media which frames sex as an 
“expression of inner desires” that every girl should be doing (Ussher, 1997, p. 4). This position is 
criticized for reinforcing strict gendered definitions of sexual freedom, the heterosexual matrix, 
and patriarchal domination over female sexuality. It does not address women’s expression of low 
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desire or difficulties achieving sexual satisfaction (Fahs, 2011). Some feminist thinkers that 
stood in opposition to the sexual liberation camp denounced sexual contact with men altogether 
as the means to achieve sexual freedom.  
To have sex or not to have sex? Pleasure can be both a source of empowerment and 
disempowerment (ibid.). Sexual liberation provided some key realizations regarding America’s 
relationship to sexuality, but it is important to recognize that the eradication of male domination 
in the sexual sphere requires an approach that goes beyond the individual. “At its worst, sexual 
liberation is part of the cult of individuality which only demands legitimization of the expression 
of the individual’s need, what appears to be her raw ‘impulse’ life, against the demands of 
society without considering a political reordering of the social order itself” (Person, 1980, p. 
629). A feminist approach that solely emphasizes female individuality, autonomy, freedom of 
choice or equality as having what men have will not successfully reform sexism in the bedroom, 
the medical field, or sociopolitical spheres.  
Addyi’s marketing and the position of Even the Score take a liberal feminist position in 
their construction of empowerment through Addyi. When operating in a system that supports 
sexopharmaceuticals, it seems ​only fair ​ that woman would have the opportunity for a sexual 
enhancement pill if men do. The argument operates under the paradigm of Viagra, a concept we 
will dive into further towards the end of the chapter. Liberal feminism platforms are centered 
around the concept of equality and improving the position of women within the existing system. 
Recognizing male domination in the sexual sphere, pro-Addyi rhetoric positions the drug as a 
way for women to demand their right to desire and reclaim power through sexual pleasure. 
However the platform fails to go beyond or outside of the dominant, masculine standard. It 
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doesn’t question or reject the need for a sexual drug in the first place, or explore how the drug’s 
position is complicated when produced in a market with ties to corporate interest and profit. 
Within this paradigm, sexual medicine is assumed to be the best solution to treat sexual problem, 
and female empowerment is conceptualized as gaining what men have. But the existence of a 
drug intervention for male sexual issues does not necessitate a drug intervention for female 
sexual issues; two wrongs do not make a right.  
The New View Campaign is not against addressing female sexual issues or improving 
low sexual desire. It doesn't denounce sexual satisfaction, but rather takes issue with current 
medical models, frameworks, classifications and solutions. In contrast to the more liberal 
feminist position in pro-Addyi rhetoric, the New View advocates for a drastic reform of society’s 
relationship to female sexuality, fundamentally denouncing the existing system as perpetuating 
the profitization and medicalization of the female body. The group has three major issues with 
the current state of sexual medicine. First of all, it ignores the relational context of sexuality. A 
diagnosis of HSDD and prescription for Addyi ignore the role of relationship factors and general 
context in a woman’s experience of sexual desire. Secondly, it assumes universality in women’s 
relationship to pleasure, ignoring the variety of opinions, needs, attitudes, experiences, 
behaviors, and issues regarding sexuality. Thirdly, it equates male and female bodies as it 
operates within the male analog, a concept that will be discussed further when exploring an 
alternative model of sexual response. The New View redefines female sexual problems as 
“discontent or dissatisfaction with any emotional, physical, or relational aspect of sexual 
experience” (Tiefer, 2001, p. 86). While Addyi supporters believe the medicalization of low 
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desire and the availability of a medical solution can work to legitimize and address their issues, 
Addyi’s opponents problematize the classification of sexual disorders in the first place.  
There is no unified, feminist position on sexual medicine or the classification of sexual 
problems such as HSDD. Arriving at a consensus would be a complicated goal; a consensus 
often requires the oppression of a minority opinion by a majority opinion and there is great 
diversity in women’s experience and relationship to sexuality. Women fighting for and against 
Addyi claim to be fighting for female empowerment, but their avenues are in direct opposition 
with one another. “In the name of women, some are genuinely working hard to find effective 
treatments for women’s sexual ‘dysfunctions,’ whereas others are just as genuinely mobilizing to 
tell women that they may be victims of a system that seeks to impose sexual standards that serve 
patriarchal and economic hegemonies” (Meana, 2010, p. 116). The medical approach falls short 
in that it perpetuates feelings of inadequacy and fails to recognize the complexity of female 
sexuality, simultaneously producing drugs which may be unsafe for women’s health. The 
sociopolitical approach may unintentionally shame or stigmatize the women who seek out sexual 
medicine to relieve distress associated with low desire. Supporting Addyi is not inherently less 
“feminist” than opposing it, however its necessary to acknowledge the ways in which Addyi 
continues to reinforce the norm, despite being framed as a “game-changer.” Is it revolutionary to 
give women the option to take a pill to increase their sexual desire within monogamous, 
heterosexual, long-term relationships without addressing the social, political, relational, cultural 




The score becomes 26 to 1 
While campaigns involving women’s organizations lobbied both for and against the 
approval of Addyi, Sprout Pharmaceuticals raised money in preparation for the hearing. By 2015 
they had raised over $15 million for the clinical trials (Schulte, 2015), had collected data on a 
total of 11,000 women in 68 trials with low sexual desire disorder in the U.S., Canada, and 
Europe (Eckert, 2017), and had raised more than $100 million from private investments to 
support its development, approval, and distribution (deBruyn, 2015). Many were eagerly 
awaiting the 2015 FDA hearing; the controversial ‘female Viagra’ had gotten a lot of attention. 
Time ​magazine listed Addyi as “the number one inanimate object that drove the news in 2015” 
(Block & Canner, 2016). In January of 2015, Cindy Eckert had 8 minutes to pitch her drug to a 
“sea of blue and gray suits” at the J.P. Morgan Healthcare Conference (Marinova, 2017). Many 
times she found herself presenting to a room in which she was the only woman, noting the social 
discomfort of most male investors that she presented to (idib.). Despite societal discomfort 
surrounding female sexuality, in August of 2015, a full 17 years after the approval of Viagra, 
Addyi finally became the first FDA-approved treatment for FSD. In Eckert’s words, “science 
had finally won” (Eckert, 2017).  
With the combination of what she considered significant evidence and an increased level 
of empathy, the “score” became 26 to 1. Although Even the Score stated “there is still a long way 
to go before we achieve true gender equity in sexual health – and Even the Score will be there 
every step of the way,” the day after the approval of Addyi was the last day they posted on their 
website (Hogenmiller et al., 2017). Is FDA approval of the first drug treatment for low sexual 
desire all that was needed for true gender equity? Many of the groups that lobbied against 
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Addyi’s approval thought that the approval was a direct result of the Even the Score campaign 
tactics. Steven Woloshin and Lisa Schwartz, physician-researchers at Dartmouth Medical School 
and the founders of pharmaceutical education company Informulary, believed that the approval 
was an override of scientific evaluation. Upon observing the data, the researchers didn’t 
understand the approval because the drug interaction was “so alarming that [the trial] was 
stopped early because so many people had low blood pressure or fainted” (Block & Canner, 
2016). Those involved in Even the Score obviously disagreed, publicly urging people to realize 
the distinction between bullying and advocacy. One activist in the campaign said ​“if the science 
didn’t support approval, the F.D.A.-appointed advisory committee of doctors, clinicians and 
other safety experts wouldn’t have approved it” ​(Tavernise & Pollack, 2015). 
Addyi’s FDA approval did not signify smooth-sailing from there on out. Its approval was 
made with certain conditions; a black box warning was issued as well as an accompanying 
REMS program due to the strong need for more evaluation and patient-specific counseling 
regarding the need, use, and safety risk of the drug (U.S. FDA, 2015). The FDA uses black box 
warnings to indicate serious or life threatening risks associated with a medication. Addyi’s side 
effects include s ​evere low blood pressure and loss of consciousness, heightened by alcohol use 
or liver problems ​(ibid.) ​. In clinical trials, participants noted dizziness, nausea, fatigue, 
somnolence, and insomnia (Moynihan & Mintzes, 2010). ​ The REMS program was initiated due 
to the risk of severe hypertension and syncope that accompanies alcohol use. It requires 
prescribers and pharmacies to enroll in a training and certification process, in addition to making 
pharmacies check prescriber’s certification prior to distributing the drug. Sprout was also 
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required to refrain from direct-to-consumer advertising for 18 months to focus on educating 
doctors about HSDD and Addyi (Thomas & Morgenson, 2016). 
The FDA was put in the position of assessing a drug for which there was little medical or 
social consensus, with experts disagreeing on either side and pressure from competing feminist 
campaigns. Regardless of the basis for or accompanying restrictions of Addyi’s approval, it was 
immediately sold by Sprout pharmaceuticals for $1 billion in cash to the pharmaceutical 
company Valeant International. The $1 billion exchange verified the confidence that Big Pharma 
had in Addyi’s potential; the drug was given a high value based on expectations that it would 
prove as revolutionary as Viagra.  
 
The paradigm of Viagra  
“In a paradigm where men’s desires reign and their power is exercised and reinforced 
repeatedly, beliefs about women as dysfunction, particularly in heterosexual contexts, 
seem far less threatening than a nonflattering assessment of men’s sexual abilities. 
Women’s ​bodies ​ become the targeted problem, not men’s ​abilities ​.” (Fahs, 2011, p. 136)  
 
Viagra was the little blue pill that changed sex in America forever (Loe, 2004). Its 
emergence ushered in the sexuopharmaceutical era, which emphasizes and rationalizes 
pharmaceutical intervention for sexual problems. The paradigm of Viagra denotes sexual 
medicine as the appropriate treatment for sexual disorders; Viagra for ED and Addyi for HSDD. 
Sexual medicine affects sexual expectations of both men and women, as the technology shapes 
and is shaped by societal norms. Operating within the paradigm of Viagra perpetuates narrowly 
define and demanding sexual behavior, requiring men to have unfaltering erections and women 
to have a consistently high sex drive. Reaching these expectations may indeed require medical 
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intervention for many individuals, which is why it is so necessary to challenge the expectations 
themselves.  
Although the development of a drug to target low female sexual desire followed a similar 
strategy to Viagra- labeling the issue as a disorder, increasing the potential audience, and 
capitalizing on gender stereotypes in the marketing of the drug as a simple solution- the hunt for 
Addyi was met with a level of ambivalence that does not play as clear a role in male sexual 
medicine. This uncertainty reflects a lack of cultural consensus and a societal discomfort with 
female sexuality. The medical and pharmaceutical fields want female desire to be neatly and 
objectively quantifiable, but that is not how female desire works. One cannot measure an 
increase in female desire the same way erectile functioning can be measured, due to the 
ambiguity and variability in disorder classification and the shifting definitions of desire.  
The story of Viagra and the early stages of the search for a female Viagra provides 
insight into the complicated process of developing and approving a treatment for FSD. Addyi 
operates within the paradigm of Viagra, which poses sexual medicine as the solution to sexual 
dysfunction. Beyond issues with safety and efficacy, the drug was politicized through competing 
feminist frameworks to sexual medicine and more generally female sexual behavior. By looking 
at the early stages of the development of a ‘female Viagra,’ I hope to highlight the lack of 
consensus on female sexual issues that currently exists in medical, academic, and social spheres. 
This will lead us into the following chapter in which I focus on the ways in which the 
pharmaceutical industry attempted to capitalize off of gendered messages embedded within 
Addyi, and yet failed to profitize successfully as in the case of Viagra. The controversy over 
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Addyi did not end at the 2015 FDA hearing, and in the following chapter we will explore how 






















CHAPTER III. THE “REAL LAUNCH” OF ADDYI AND THE PINK CEO 
“For me, pink is about owning it as a woman. You have two options when it comes to gender 
stereotypes-you can either rail against them, have them paralyze you in frustration, or you run 
right toward it as I do. Pink, for me, became the transition from underestimated to unapologetic. 
When people said I had a ‘little pink pill’ and patted me on the shoulder, I understood there was 
some dismissiveness there, and that’s what needed to be addressed. So I started wearing hot 
pink.” - Cindy Eckert (Marinova, 2017) 
 
Addyi’s position in the sexopharmaceutical era has been complicated, in stark contrast to 
the development, approval, distribution and marketing of Viagra. A promising billion dollar deal 
with an international pharmaceutical company did not produce the predicted market success, 
initially due to issues with cost, distribution, insurance coverage, and the HSDD educational 
campaign. Despite constant setbacks to the drug’s availability, Cindy Eckert’s determination to 
fight for Addyi did not falter. Eckert became a leading figure in the marketing campaign for the 
drug. Labeling herself the “Pink CEO,” she took to social media and press coverage to educate 
the public about Addyi and it’s potential to be a sex-saving drug. Eckert frames Addyi as 
providing women access to the choice to reclaim their sexual desire. She also frames it as a 
matter of female representation in the medical and pharmaceutical fields. This chapter recounts 
the challenges faced in the introduction of Addyi, the necessary relaunch, or rather “real launch” 
(Godnick, 2018) of Addyi in the summer of 2018, and the role of Eckert in the gendered and 
heteronormative marketing of the drug. This timeline forms the foundation by which I will 
explore the reasons behind Addyi’s failure to be as revolutionary as Viagra its reinforcement of 
sexual normalcy consistent with conventional, heterosexual norms. As Eckert said in the opening 
quote, the production and distribution of Addyi required her to run towards gender stereotypes 
rather than let them paralyze her. But what are the social implications of operating within the 
O’Bryan 47 
existing paradigm in which sexual medicine plays a large role in our interactions with desire, sex 
and sexuality?  
 
Addyi’s first flop on the market  
Sprout pharmaceuticals raised a lot of money and conducted a considerable amount of 
research to get Addyi approved, but it was a small company that would need help in the 
marketing and distribution process. At the time of Addyi’s approval, Valeant was doing really 
well; it posted revenue of 8.3 billion in 2014 with 18,000 global employees. Valeant promised to 
retain all of Sprout’s employees and allow Sprout investors to remain entitled to future profits 
(Pollack & Bray, 2015) ​. Aware that the controversy surrounding the drug would make it difficult 
for Sprout to find an interested buyer, Valeant’s chief executive believed their company was 
Addyi’s best bet to do really well on the market (ibid.). Cindy Eckert noted that the partnership 
with Valeant “brings access to more women, more affordable access, and takes it across the 
globe” (Eckert, 2015).  
It became very clear a few months after the billion-dollar exchange that Addyi was not 
making the splash Sprout had hoped it would; in fact almost everything that could go wrong did. 
Within a few weeks of Valeant’s purchase, the international company faced allegations of 
improper accounting and hiked drug price ( ​Gandel & Reuters, 2016). Prominent politicians such 
as Bernie Sanders requested information on why they hiked the price of two heart drugs, which 
was discovered to be common practice for the company; they increased the price of medications 
by an average of 66 % (ibid.). Off the bat, Valeant doubled the price of Addyi and severed ties 
with the planned distributor (Thomas & Morgenson, 2016). Within the first three to four weeks 
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of Addyi’s launch, the demand was incredibly low; in the first month only 277 women were 
prescribed Addyi compared to Viagra’s half a million prescriptions (Armstrong, 2015; Edney & 
Colby, 2015). ​Despite the attention in the press and online, women were making the decision not 
to take Addyi, potentially due to the questionable efficacy, potentially harmful side effects, and 
lack of general knowledge regarding both the disorder and the drug. Due to the FDA’s REMS 
program, doctors were required to watch a ten-minute informational video and fill out paperwork 
in order to prescribe Addyi. Without basic promotional materials or a comprehensive educational 
campaign, Addyi’s team of 150 sales representatives was ill-equipped to address the 35,000 
OBGYNS and 450,000 primary care doctors in the U.S. ​(Thomas & Morgenson, 2016); only 
4,000 prescriptions written between February and September 2016 at a monthly cost of $800 
(Block & Canner, 2016). This meant a monthly average of 600 prescriptions were written 
compared to almost 800,000 for Viagra and Cialis (Koons, 2018).  
Another hurdle Addyi faced was insurance coverage, despite the fact that Viagra is 
covered by most insurance companies. Dr. Goldstein from the ​Sexual Medicine Society meeting 
in 2010 and ​ now a paid Sprout consultant called the difference in coverage was startlingly sexist 
(Cohen, 2016), although Valeant had doubled the $400 per month price that Anthem Insurance 
agreed it would cover (Thomas & Morgenson, 2016), but under Valeant the cost had doubled. 
One woman with Blue Shield Insurance was refused coverage for Addyi because the company 
required a psychiatrist’s diagnosis of HSDD and because she was on a medication that had a 
potential side effect of low libido (Paiella, 2016). The spokesperson for Blue Shield California 
responded to CNN’s coverage on the woman’s experience by saying that a committee of 
pharmacists, physicians, and psychiatrists reviewed the medical evidence and determined that 
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HSDD should be diagnosed by a psychiatrist, as the black box warning necessitates a careful 
diagnosis before taking the drug (ibid). This reflects a general lack of understanding of how to 
diagnose and classify HSDD. The woman would have to pay $800 a month for Addyi while her 
boyfriend’s Viagra was covered even though he does not have erectile dysfunction and takes the 
drug as an enhancer. A spokesperson for ​America's Health Insurance Plans also chimed in to say 
that the FDA’s eventual approval of Addyi was a result of the Even the Score campaign rather 
than convincing data, because "if there's a question mark around a coverage decision, that 
usually means there's a question mark around the efficacy" (Cohen, 2016). ​The National 
Women’s Health Network’s one-year report card for the anniversary of Addyi’s FDA approval 
assigned Addyi a D for doctor training and an F for natural demand, calling the safety training 
program “laughably bad” (NWHN, 2016). Valeant tried to blame the small sales on female 
patients’ reluctance to take the drug rather then on the failure of the training program, as 82% of 
prescriptions written were going unfilled in 2015 (Wieczner, 2017). Cindy Eckert has claimed 
that the modest sales are a result of the FDA restrictions on a direct-to-consumer marketing 
campaign and the need to educate the public, medical professionals, and medical providers about 
Addyi and HSDD (Eckert, 2017a).  
Whether Valeant was not interested or not able to sell Addyi effectively, the drug that 
was supposedly entering a large market of unmet need was set to generate less than $10 million 
in sales in 2016 (Wieczner, 2017). ​Addyi had not lived up to its expectations and Valeant was 
facing a lawsuit for its failure to meet the obligations named in the billion-dollar-exchange. 
Sprout shareholders sued the pharmaceutical company and Valeant decided that returning Addyi 
to its original owner was better than fighting Sprout in court or launching a revamped marketing 
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campaign. Sprout reclaimed Addyi along with an additional $25 million, which would be used to 
cover startup expenses as they prepared to relaunch the drug in 2018.  
 
The “Real Launch” of Addyi and the ethics of accessibility  
By the summer of 2018, Addyi had faced three rejections from the FDA, a failed launch 
after FDA approval, and a lawsuit. Finally it was back in the hands of Cindy Eckert at Sprout 
Pharmaceuticals and ready to re-launch to the public. Because of the sensationalism spurred by 
the media and the controversy among feminists, medical experts, and women’s organizations, 
Addyi’s re-emergence was long-awaited. If Sprout wanted the drug to make a bigger splash this 
time around, it would need to step up its distribution strategy and bypass the restrictions imposed 
by the FDA’s REMS program. This was largely accomplished by the use of telemedicine. 
Accessibility was one area that proved very difficult for Addyi under Valeant’s 
ownership. As Eckert said, ​“it was theoretically in the supply chain, but for a woman to have 
gotten this drug in the last two years was like winning the Powerball” ( ​Marinova, 2018). Sprout 
slashed the price back to $400 a month, meaning those with insurance coverage would pay $25 a 
month while those without coverage would pay $99 a month (Koons, 2018). Although cheaper, 
the avenues of education still needed to be defined. In order to address the lack of doctors and 
pharmacies who were knowledgeable of HSDD and certified to prescribe Addyi, the drug 
became accessible via telemedicine. Before 2018, only 10% of the pharmacies in the country 
stocked the drug (MacKenzie, 2018). With telemedicine, women could consult a doctor from 
anywhere in the country and have the drug delivered by mail to their doorstep. However through 
Sprout the required consultations cost an out-of-pocket fee of $75, considerably complicating 
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their financial accessibility. Accessibility as represented by Sprout’s consultation fee as well as 
their partnership with the telemedicine brand Hers, gives insight into the audience they are trying 
to reach. 
Sprout partnered with the telemedicine brand Hers, a direct-to-consumer sister company 
to the several year-old site Hims. Hims launched to sell hair loss and erectile dysfunction drugs 
and in the first week already had $1 million in sales (Tindera, 2018). It had $97 million in 
venture capital funding from investors to launch Hers, a female equivalent which would sell skin 
creams, birth control, and of course Addyi (ibid.). The website uses rhetoric similar to Eckert’s, 
claiming “women have been pat on the shoulder and ​ignored ​ when it comes to giving us a 
solution to this ​very real​, very common concern.” The drug is framed as a game changer that will 
address female low libido and allow women to reclaim their sex drives. Although attempting to 
make Addyi more accessible, Hers doesn’t accept insurance. That means the women who use it 
have to pay $99 a month. When asked why anyone would want to pay $99 when an insurance 
plan can potentially cover the drug, Hers said that its goal is to put power back in the hands of 
women, addressing gaps in accessibility by allowing an alternative, more convenient and discreet 
way to get Addyi. This could benefit women with demanding work schedules or who don’t want 
the drug to show up on family insurance records, but it does so at the expense of economic 
accessibility. While direct-to-consumer telemedicine can allow for easier, more discreet access to 
Addyi, it can potentially compromise affordability. 
Widespread accessibility is vital for a drug to be able to reach a large audience across 
geographic and socio-economic lines, yet there is a lot of controversy regarding the ethics of 
telemedicine as a route to access. Telemedicine is becoming more common as technology has 
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evolved to create new and alternative communication and distribution pathways in medical care 
and pharmaceuticals. One main concern for the rise of these alternative patient-provider 
interactions is the implications of the loss of face-to-face consultations. The American Medical 
Association (AMA) has emphasized the need for telemedicine to be used only as a complement 
or supplement to live visits, and be reserved for patients who have a relationship or history with 
the provider (Mehta, 2014).  The Texas Medical Board (TMB) stated that prescribing medicine 
without this pre-existing relationship has the potential to compromise safety and efficacy (Worth, 
2015). One has to be especially careful with telemedicine in the case of Addyi, a highly 
controversial drug with a black-box warning. The DSM-V has supposedly evolved through the 
inclusion of partner factors, relationship factors, vulnerability factors, stressors, cultural and 
religious factors, and medical factors., but when these consultations are occurring online and 
over the phone, will a doctor take the time to ask questions that will deepen their understanding 
of the complexity of their patient’s relationship to desire? And with the price of these 
consultations, whose accessibility is being prioritized?  
 
All pink, all the time 
After Sprout reclaimed ownership of Addyi from Valeant, Eckert became a leading figure 
in the marketing campaign for the drug. Labeling herself the “Pink CEO,” she took to social 
media and press coverage to educate the public about Addyi and its potential to be a sex-saving 
drug. Through the employment of gendered advertising, Cindy Eckert and her drug became all 
pink, all the time. In addition to increasing accessibility and recognition of the drug, Eckert 
became somewhat of a celebrity-  she was the woman behind ‘female Viagra,’ supposedly 
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changing stereotypes and championing women’s rights. Addyi was one step in her mission to 
unapologetically empower women, in both private and public spaces. But the connection 
between sexual medicine and female empowerment is the result of the successful marketing of 
Viagra; the new “Viagra wives” must keep up with their husbands. 
“Your brain may be working against you when it comes to sex,” reads the text on 
Addyi’s website above an image of a heterosexual couple in bed, peeking out from under the 
covers (See Photo 1 in Appendix). A little farther down the page there are two images of a brain, 
one labeled “healthy” and the other “HSDD” (See Photo 2). The healthy brain is lit up in pink, 
while the HSDD brain has only small blotches of pink here and there. Below is a bold text blurb 
stating “millions of premenopausal women suffer from distressing low sexual desire.” This 
statistic is informed by a Boehringer Ingelheim funded study of sexual problems experienced by 
U.S. women in 2008 (Shifren et al., 2008). Investigating further into the study shows several key 
observations not included on Addyi’s website. Sexually related personal distress was observed in 
only 22.8% of respondents, and the prevalence of sexually related personal distress associated 
with the presence of any of the three sexual problems of low desire, low arousal, and orgasm 
difficulties was only 12%. Though the study acknowledges the significant association between 
distressing desire problems and socioeconomic and demographic variables such as race, partner 
status, employment, and level of education, over 80% of the respondents were white women, and 
the majority of respondents were college-educated, employed, and in steady relationships. From 
this information, Sprout simply concludes that millions of women are suffering from distressing 
low desire.  
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Similarly to the all-blue Viagra website, Addyi’s website is entirely pink. As Eckert 
explained, “pink is about owning it as a woman” (Marinova, 2017). Not only is Addyi pink, but 
so is Cindy Eckert. At almost every promotional event, Cindy sports hot pink; pink pant suits, 
pink dresses, pink heels, pink glasses, pink frilly sleeves, sporting little pink pill (See Photo 3). 
Through her eyes, the employment of gendered marketing is a way for her to reclaim a 
stereotype. Making Addyi the little pink pill is in line with sexopharmaceuticals’ production of 
gendered meanings for drug users. Cindy Eckert spearheaded the marketing of Addyi and was 
the driving force behind it’s approval, distribution, and media presence. She took to social media 
and the press to garner attention, accumulating just shy of 12,000 followers on Instagram and 
27,000 followers on Twitter. In her Instagram bio, Cindy describes herself as an “entrepreneur 
by skill, unapologetically pink by nature, helping others shatter The Pink Ceiling by choice..oh 
btw $1.5B in exits, (but who’s counting?).” Underneath her bio is a link to the Voters’ Choice 
Awards by WRAL, a radio station in Raleigh, North Carolina in which Cindy was voted runner 
up for Woman of the Year. The instagram also serves to update followers on the work Eckert is 
doing, such as her position as the annual Raleigh Christmas Parade Grand Marshal and the 
speaker at Birmingham Venture’s annual meeting. She’s been featured in many magazines, 
named one of ​Entrepreneur ​’s “Women to Watch,” ​Triangle Business Journal’ ​s “People to 
Watch” and ​Inc Magazine​’s “Female Founders 100.” Eckert has conducted interviews with 
CNBC, Fortune magazine, Entrepreneur, Forbes ​, among others. She has even given her own 
Ted Talk on the intentions behind Addyi, illustrating how it stems from empathy and a 
willingness to change the game for the sake of women’s control over their own sex lives (Eckert, 
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2017b). Through positioning herself as a feminist figure, she uses gender stereotypes to her 
advantage in order to gain traction in a field traditionally dominated by male voices. 
Eckert is featured in these magazines, interviews, and news stories as a result of her role 
in the production of Addyi, but also because of the Pink Ceiling, the venture capital firm and 
consulting enterprise she opened in 2016 with part of the funds from the billion-dollar Addyi 
deal. The name is a reference to the glass ceiling that bars women and other minorities from 
corporate spaces such as the pharmaceutical industry; as Eckert said ​“the thesis is: let’s stack the 
billion-dollar club by smashing the pink ceiling together” (Smith, 2018). ​Out of the Pink Ceiling 
came the the Pinkubator, a startup incubator in Raleigh focused on helping female entrepreneurs 
launch new products and companies. The Pinkubator, rumoured to have rosé on tap, has the 
mission of making other women “really f**cking rich” (Robinson, 2017). ​ ​It is worth noting that 
Eckert’s work with the Pink Ceiling and the Pinkubator does provide important funding and 
mentoring resources for women-led or women-focused businesses through Addyi’s accumulated 
profits. Although its mission is to support female-led business and increase female representation 
in fields that are traditionally exclusively male, it does not make Addyi less controversial. Eckert 
links Addyi and the Pinkubator in that the latter works to put money in the hands of women as 
Addyi did for her. In discussing the goal of the Pinkubator, she said ​“we talk all the time about 
how women need a voice. We don’t need a voice- we need power. Money is power. I say that 
confidently because the data shows that when women have that power, they pay it forward” 
(ibid.). ​She believes women have found their voice, and the missing piece is money. This gives 
insight into her priorities for female empowerment; her position in the Pinkubator ​shows that she 
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is prioritizing money as a form of female empowerment. But have all women found their voice? 
Which women’s voices do we value and uplift?  
 
Corporate Feminism: Your body, your choice 
“The history of drawing on feminist language and theory to sell products has been driven 
by the idea that female consumers are empowered by their personal consumer choices- 
indeed, that choice, rather than being a means to an end, is the end itself. The idea that it 
matters less ​what​ you choose than what you have the right to choose is the crux of 
‘choice feminism’...” (Zeisler, 2016, p. 18) 
 
Addyi is situated at the intersection of medicine, gender, sexuality, and capitalism. It is a 
medical technology, but it is also a product within a market. Potential patients become potential 
consumers, and their understanding of and relationship to the drug is shaped by its advertising. 
The corporate interests in selling drugs embedded with gendered messages is a concern for many 
women (Fahs, 2011). Addyi’s marketing strategy capitalizes on feminist rhetoric; the drug 
represents the key to female sexual empowerment, the choice to reclaim power over female 
sexual lives, the fight against sexism in sexual medicine, and the means to make women really 
f**cking rich. Andi Zeisler’s ​We Were Feminists Once ​provides an insightful analysis into the 
ways in which feminism has been rebranded and co-opted by mass media to drive marketing and 
advertising campaigns. Though the author doesn’t focus on sexual medicine, her account of how 
feminism is bought and sold can be useful in framing Addyi.  
The selling of Addyi relies on the medicalization of female bodies to meet societal 
expectations. Products geared towards female audiences, especially of a white, middle-class 
background, are often marketed to address a problem that “the consumer might not ever know 
she had until she was alerted and/or shamed for it” (Zeisler, 2016, p. 25). They depend on the 
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creation of insecurity, often in line with cultural expectations of gender. Advertisements use 
rhetoric to appear in the spirit of feminism, yet capitalize off of addressing the insecurities that 
they create or perpetuate. While the framing of Addyi by Sprout Pharmaceuticals and Cindy 
Eckert may seem less obvious than Zielser’s example of the “freedom spray” aerosol douche or 
the “Liberated Wool Sweater” (ibid., p. 7-8), the company capitalizes off of cultural insecurities 
related to expectations of femininity.  
Addyi’s marketing campaign adopts choice feminism by employing feminist messages to 
advertise and profitize through building on the idea that any choice made by a woman is a 
feminist choice. In this “empowertising,” having the option to take the drug becomes an 
expression of liberation in itself (ibid.). Choice plays a big role in Eckert’s discussions regarding 
Addyi; in a 2018 tweet she wrote “this is about choice- women can take Addyi or not take it, but 
for women who need it, they deserve the option” (MacKenzie, 2018). The power of choice 
coincides with the power of the purse, an important tenet of marketplace feminism. Who holds 
the power to purchase Addyi, and which women does Addyi make “really f••cking rich”? 
According to Zeisler, the easy target demographic of feminist advertising is and has historically 
been white, middle and upper class, cisgendered women. One relevant critique of choice 
feminism that is especially relevant to Addyi is that it disregards limits posed by socioeconomic, 
political, or racial barriers, assuming the choice is accessible to everyone. “We know logically 
that choices aren't made in a vacuum: we assign financial, aesthetic, and moral value to any 
number of choices in the course of each day, and most of us get that these choices mean 
something in our larger world” (Zeisler, 2016, p. 187). It’s necessary to challenge the idea that 
choice is a tool for empowerment in itself, regardless of the choice made or the implications of 
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the availability or promotion of that choice. The prominent rhetoric of Addyi’s marketing frames 
empowerment as centering on technological equality and individualized choice. 
 
‘Female Viagra:’ A very different story  
Although given the name ‘female Viagra’ before it was even discovered, Addyi was not 
the game-changer for women’s sexual lives that Viagra became in the turn of the 21st century. It 
wasn’t that there was no interest for a female sex-saving drug; it was clear that ​the funding, 
research, interest, and supposed unmet market existed since the early 2000s. Yet Addyi’s story 
was not as straightforward as Viagra’s, which was fast-tracked through the FDA approval 
process and introduced to the market with staggering sales. Cindy Eckert has said herself that 
Addyi is no Viagra, highlighting the different mechanisms of the drugs’ function. But the 
difference goes beyond what area of the body the two drugs target; Addyi has been the topic of 
feminist debate and media controversy, and has faced three FDA rejections, advertising 
restrictions, black box warnings, and unimpressive sales. So, why is Addyi failing to be for 
women what Viagra is for men?  
Beyond the fact that Addyi and Viagra work differently, the mechanisms of Addyi create 
a high barrier for usage. For one, the drug is a long-term commitment, as it must be taken every 
day over the course of several months in order to judge efficacy. The safety is a point of concern 
for potential users and was a large part of the FDA’s rejections. Individual women have 
expressed apprehension about its safety (Fahs, 2011), in addition to various organizations and 
researchers ​(Block & Canner, 2016) ​. The National Women’s Health Network went so far as to 
launch a campaign in the wake of Addyi’s approval called “Pass on the Pink Pill- or Pass Out!” 
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to warn women of the risks of low blood pressure, dizziness, and sudden loss of consciousness. 
Addyi’s black box warning strongly discourages alcohol use, as it increases ​severe hypotension 
and syncope risk. Under the drug interaction section of Addyi’s drug monograph, as found on the 
U.S. health network Athenahealth website, over 40 substances are listed as contraindicated, over 
70 are advised to avoid, and over 200 are listed as important to monitor while using Addyi 
(Epocrates, n.d.). These safety concerns, in combination with the low efficacy rates, play a role 
in the low number of users.  
The lack of knowledge about the drug and the original challenges faced in distribution 
presented high barriers for access. As Eckert said, getting the drug would have been like winning 
the Powerball in Addyi’s first two years in the supply chain. The ban on direct-to-consumer 
advertising and the REMS program made it difficult for medical professionals and women to 
even be aware of the drug in the first place. In addition, Valeant severed ties with the distributor, 
failed to launch an effective educational program, hiked the prices, and couldn’t get insurance 
coverage of the drug. These variables created an initial setback for Addyi’s emergence, and 
though some were addressed in the relaunch of the drug in the summer of 2018, the safety 
concerns, low efficacy rates, high price, long term commitment, and lack of knowledge continue 
to play a role in Addyi’s inability to revolutionize the female sexual experience.  
Beyond the mechanisms of the drug and its high barrier for usage and access, some have 
pointed to the role of potential cultural understandings of female sexuality in the difficulty of 
finding a successful ‘female Viagra’. Researcher and professor Rebecca Kukla considers the 
attempt to medicalize female sexuality a failure, highlighting several cultural reasons that 
worked to resist medicalization. These reasons include the conceptualization of female sexuality 
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as useful for other reasons outside of the pursuit of pleasure, unlocatable to one specific part of 
the body, mysterious and unpredictable, and fragile and context-dependent (Kukla, 2017). 
Whether there is truth in these cultural understandings is besides the point, because their 
importance is in the role they play in Addyi’s failure.  
Kukla points to the notion of female sexuality as serving a purpose beyond the pursuit of 
pleasure, woven into social narratives specifically as a way to negotiate, control, or manipulate 
male behavior. This functions to link sexuality to social needs and narratives, and challenges the 
idea of an effective physiological intervention. Women have sex for a variety of reasons both 
within and outside of the quest for physical pleasure. Studies have shown that some of women’s 
primary reasons for engaging in sexual activity are to satisfy a partner, avoid interpersonal 
conflict, promote relationship intimacy, avoid rejecting a partner, express love, escalate depth of 
connection, explore curiosities, and celebrate (Meana, 2010). Desire can be present even if sex is 
not the goal, but rather the means. Should the motivating goals of closeness, intimacy and 
relationship maintenance be considered a part of female sexual desire, or considered a collection 
of non-desire-based motives? Should there be a distinction between sexual activity pursued 
because of these motives and sexual activity pursued because of a physical, pleasure-focused 
motive? If female sexual desire is thought to be connected to all of these different identities and 
goals, in contrast to the cultural perception of male sexuality’s link to erectile functioning and 
pleasure, a successful solution to female sexual issues is not going to be an easy find.  
The notion that female sexual behavior operates to serve social purposes also works in 
other ways that complicate the search for a ‘female Viagra’. It is interesting to think about the 
relationship between sexuality, masculinity, and femininity. Meika Loe, author of ​The Rise of 
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Viagra ​, recounted a conversation she had with a U.S. doctor and his patient in order to illustrate 
how masculinity is often perceived as inherently linked to sexual pleasure. According to this 
doctor, a functioning penis is integral to the male identity. “For many men the idea of not being 
able to ‘get it up’ is a fate worse than death” (Doyle, 1983, pg. 205). As we saw in Chapter 2, 
this link between sexual function and manhood was capitalized on by the marketing of Viagra. 
Pfizer was selling a drug to address “a symptom of ‘failed’ masculinity” (Johnson & Asberg, 
2017, p. 88). Most of Loe’s male interview subjects were in agreement with this attitude, which 
makes sexuality a requirement for masculinity and constructs femininity in opposition to both 
masculinity and sexuality (Loe, 2004). Female sexuality is tied to social mechanisms beyond 
sexual pleasure, as sexual endeavours can be a tool for social negotiation, a fulfillment of the role 
of mother and wife, and an instrument of intimacy.  
The trope that female behavior, thoughts, moods, and sexuality are unpredictable and 
mysterious can be traced back many centuries and is still present today. Beyond the mystery of 
what female sexuality is and how desire functions, is the question of where it is located. Female 
sexuality can’t be isolated to one part, as it’s conceived as ever-shifting, everywhere, and 
nowhere. Low female sexual desire can’t be solved with a pill that enhances blood flow to the 
genitals nor one that targets the brain. D ​esire is not a concrete, easily-definable concept, and it 
has no consistent referents. Without consistent referents, it is incredibly difficult to identify 
criteria for HSDD diagnosis. ​ While the cultural understanding of female sexuality as mysterious 
and unpredictable works to resist medicalization, it has also been noted as an excuse as to why 
female sexual issues are too difficult to address; “ ​women are just too complicated to measure. 
Everyone was saying this, from transport planners, to medical researchers, to tech developers: 
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they were all knocking their heads up against Freud’s riddle of femininity and coming away 
baffled and defeated. Female bodies are too inharmonious, too menstrual and too hormonal” 
(Perez, 2019, p. 314). In order for positive resistance to medicalization, it must be accompanied 
by efforts to create a deeper understanding of female sexual health rather than used as an excuse 
to remain ignorant.  
What do women want? As Kukla points out, this question has been the subject of much 
debate in popular culture, medical literature, and interpersonal conversations. Addyi relies on 
this question, because the diagnosis of HSDD rests on the discrepancy between what women feel 
and what they ​want​ to feel. It is supposed to be revolutionary, and yet it capitalizes on 
conventional standards of normalcy.  
“I’ve pretty much given up hope. My marriage is OK because my husband is a good 
man. We have sex whenever he can’t take it anymore. I think we have both settled on 
that, but I still wait for the day he asks for a divorce...I hope it gets approved to that 
other women won’t have to go through what I am...I just wanted to write this and say 
thank you. Thank you for not telling me it’s my fault. Thank you for not telling me 
it’s all in my head. Thank you for not telling me that I am broken and I am not 
fulfilling my wifely duties only because I don’t want to. Mostly, thank you for letting 
me know I am not alone.” -Addyi user (Eckert, 2017b.) 
The quote above is from a woman in Texas who reached out to Cindy Eckert to express her 
yearning for the approval of Addyi. She brings up important points regarding how the medical 
diagnosis of HSDD and availability of Addyi relieve her of personal stress and guilt associated 
with low sexual desire. There is a theme present in this quote as well as in the testimonials of 
other female users and resistors of Addyi: distress related to an inability to keep up with a 
standard of normal sexual libido, whether that standard is based on cultural sexual scripts, a 
previous level of libido, or a measurement based on a partner’s desire.  
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In ​Performing Sex: the making and unmaking of women’s erotic lives ​, author Breanne 
Fahs draws a key observation regarding women’s varied reactions to ‘female Viagra’. In the 
interviews she conducted with women who were supportive of a pharmaceutical treatment for 
low desire, the disconnect between a woman’s experience and her expectations regarding desire 
was especially clear. There was concern, fear, and frustration surrounding low libido and the 
inability to alleviate sexual pressure from partners (Fahs, 2011). The requirements of Addyi’s 
clinical trials participants to be cisgendered women in long-term heterosexual relationships, the 
language used in the medical literature, Sprout’s advertising campaign and relationship to 
accessibility, and the rhetoric employed by Cindy Eckert work to privilege specific bodies and 
sexualities. The classification of disorders and medical interventions work to denote what is 
normal and natural from what is not. In the case of sexual disorders, “to act sexually is deemed 
natural, normal, to not act, unnatural, abnormal” (hooks, 1984, p. 151). Sexual abnormality 
becomes behaviors that stray from “genital-centered, intercourse-oriented, heterosexuality based 
on love and monogamy” (Seidman, 2010, p. 7). This renders certain identities and expressions 
atypical and deviant. 
Feminist critiques on the role of sexual medicine in keeping women in the conventional 
roles of partner, wife, or mother reveal a parallel to early notions of frigidity discussed in the first 
chapter. The diagnosis of frigidity was centered around traditional notions of femininity and 
heterosexuality, accompanied by an emphasis on the importance of sexual pleasure in 
maintaining marriage. Addyi as a treatment for HSDD holds a similar power, still reinforcing 
narrow rules as to what constitutes “normal” sexual behavior that are consistent with 
conventional, heterosexual norms. In the design and development of drugs to target FSD, the 
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expectation is that a normal woman should be sexually serious, easily aroused, fully lubricated, 
and orgasmic (Loe, 2004).  
While challenging the conceptions of female sexual normalcy is vital, I do not wish to 
undermine the experience of distress associated with low libido. As Fah’s interviews illustrated, 
distress is often rooted in the discrepancy between a woman’s libido and that of her partner, as 
well as between what a woman actually feels and what she thinks she ​should ​ feel. Low sexual 
desire is the most common presenting sexual complaint in women, reported at much higher rates 
in women (Meana, 2010). This raises questions about societal conceptions of female sexuality 
and desire, and the social implications of sexual medicine’s role in our interactions with desire 
and sex. What do we consider “normal,” and what would be the ramifications of challenging, 
resisting, or redefining normalcy?  
Female sexual desire is not a simple concept. There is a lack of consensus in the feminist 
community and the medical field towards desire and sexuality, evident in the varied and 
changing clinical definitions and models of desire. Kukla’s fourth cultural understanding of 
female sexuality that works to resist medicalization within current medical frameworks is the 
notion that female desire is fragile and context-dependent. Personal, sociocultural, or relational 
contexts do not play a role in the contemporary hegemony of female sexology, which in turn 
creates difficulties in effective design and development of treatments. Models of sexual desire 
and sexual response continue to emerge; I will present one in particular in the following chapter 
that centers the importance of context, challenges the dominant framework as represented in the 
FSD literature and the DSM, and ​illustrates how contemporary standards misconceive of sexual 
functioning in the medicalization of female sexual issues. 
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CHAPTER IV. DISPUTING ESSENTIALIST CONCEPTIONS OF FEMALE SEXUALITY 
“Whatever your experiencing in your sexuality- whether its challenges with arousal, desire, 
orgasm, pain, no sexual sensations- is the result of your sexual response mechanism functioning 
appropriately...in an inappropriate world. You are normal; it is the world around you that’s 
broken.” (Nagoski, 2015, p. 9) 
 
The dominant models of sexual response that inform contemporary classifications of 
disorders are rooted in conceptions of sexual normalcy. I will argue that we define existing 
sexual disorders through a flawed model, which results in problematic and ineffective drug 
interventions. In the previous chapters, I looked at the evolving nature of the classifications of 
female sexual dysfunction, examined the problems faced in the introduction of the only FDA 
approved pharmaceutical for low female sexual desire, and argued that Addyi falls short as a 
‘cure’ for HSDD. I contend here that there is a need for a more nuanced model of sexual 
response, and propose the Dual Control Model (DCM) as a more appropriate, comprehensive 
approach to sexual response. Emphasizing the importance of context, variability, and the female 
experience, the DCM challenges and potentially rejects the ​foundation by which Hypoactive 
Sexual Desire Disorder is defined. In presenting the DCM as one alternative model of sexual 
response, I will explore the potential ramifications of its acceptance on the current definition of 
female dysfunction.  
As we have seen, the female experience is not always centered in the production of 
medical knowledge regarding female bodies. Research notes the phenomenon of medical 
professionals ignoring significant health concerns reported by female patients; the 
sexopharmaceutical era is characterized by a focus on female sexual issues of pleasure over those 
of pain. Endometriosis, polycystic ovarian syndrome, and pain disorders relating to sexual 
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activity have not been the subject of as much attention as low female sexual desire (Moynihan & 
Mintzes, 2010). Cindy Eckert applies this phenomenon to sexual medicine, stating “ ​I saw this 
portrait of a woman, a woman who had raised her hand many times along the way and said, 
‘something's wrong, something's changed, something's different,’ and had been patted on the 
shoulder and dismissed...What ignited me is that we have a medical condition that we have 
known about since the 70s and yet we're still patting women on the shoulders and telling them to 
relax” (Mackenzie, 2018). Eckert’s connection is short sighted in that it ignores the long history 
of a hyperfocus on female sexuality, with female sexual desire becoming increasingly 
emphasized in medical and academic literature following the gravitation towards a biological, 
essentialist approach to sexual behavior in the later 20th century (Meana, 2010). There have been 
efforts to quantify, study, address, and cure low female sexual desire for decades, heightened in 
the quest for a ‘female Viagra,’ because there is social utility in female sexual functioning within 
its promotion of successful long-term partnerships and reproduction. Although there has been 
effort and attention directed towards developing a drug treatment for HSDD for many years, the 
process of finding an effective one is difficult and complicated due to the misinformed scientific 
and technological approaches taken to understand and address female sexual issues. 
Low female sexual desire is framed as abnormal through the production of medical 
research, literature, disorder manuals, and pharmaceutical interventions. It implies that there is a 
normal level of sexual desire that the majority of women experience, and therefore those who fall 
outside of that majority are disordered. According to Laumann in his 1999 article, 43% of 
women aged 18 to 59 have female sexual dysfunction. If just under half of women are classified 
as “disordered” under the current assumptions of sexual response, the narrow bounds of 
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normalcy must be reconceptualized. In reality, there is great variability in female sexuality that 
cannot be encompassed in the current models and definitions of sexual normalcy in the DSM. 
Female sexual normalcy is defined within male-dominated paradigms. The male analog 
functions to equate the male norm for natural and normal sexual behavior to all bodies. Caroline 
Criado Perez, author of ​ Invisible Women, ​ coined the term the “gender data gap” to describe the 
process of structuring the world according to the male body, in all walks of life including the 
medical field (Perez, 2019). As an example of the gender data gap at play in pharmaceutical 
development, Perez explicitly references the use of 23 male and 2 female participants in Sprout’s 
clinical trial on Addyi’s alcohol interaction, despite well-documented data that shows male and 
female bodies process alcohol differently (Schumaker, 2015; Harrison, 2015; Thomasson, 2002). 
These practices have serious consequences for female drug users in terms of safety and efficacy.  
The male analog plays a large role in the definition of desire that characterizes the human 
sexual response cycle. I discussed the competing theories of spontaneous and responsive desire 
in the first chapter. The DSM assumes spontaneous desire, but studies have shown that only 15% 
of women tend to experience spontaneous desire in contrast to 75% of men. Furthermore, about 
30% of women tend to experience responsive desire, while the remaining 50% or so experience a 
combination of the two (Nagoski, 2015). If drug development is conducted within the paradigm 
of Viagra and with an understanding of female sexual response filtered through the male analog, 
is Addyi’s low efficacy rate a surprise? Through applying knowledge and models based off of 
male bodies, omissions and assumptions are often made regarding the complexity and nuance of 
female desire and sexual response. This in turn hinders appropriate and accurate design of 
treatment. I do not intend to suggest a caricaturization of sexual response with male sexuality 
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understood as simple and female sexuality as complex; that is not supported by biological or 
social studies of sexuality. Rather, I seek to explore the implications of medicalizing female 
sexuality within heteronormative, male-dominated sexual norms and highlight an alternative 
model that challenges contemporary classifications of female sexual dysfunction.  
 
The Dual Control Model: how it works  
The human sexual response cycle used in the DSM classification of sexual dysfunction is 
problematic in the way it reinforces misunderstandings about female sexual desire and response. 
It is too linear, too simple, too universal, and too male. In her book ​Come as you are​, Dr. Emily 
Nagoski raises attention to an alternate model of sexual response that accounts for individual 
variability called the Dual Control Model (DCM), created by Erick Janssen and John Bancroft at 
the Kinsey Institute (Janssen & Bancroft, 2007). Under this model, the mechanisms in the brain 
that coordinate sexual response behave in the same way as those that coordinate other aspects of 
the nervous system, which function through the dynamic partnerships of accelerator and brake.  
The sexual accelerator, or Sexual Excitation System (SES), functions by constantly 
scanning an individual’s internal and external environment for sexualy relevant stimuli- “things 
you see, hear, smell, touch, taste, or imagine” (Nagoksi, 2015, p. 48). The information triggers 
the SES to send signals from the brain to the genitals. The sexual brake, or Sexual Inhibition 
System (SIS), is composed of two levels of brakes which send neurological “off” signals. The 
first brake functions similarly to the accelerator in its reliance on context, scanning the internal 
and external environment for potential or immediate threats. In Dr. Nagoski’s words, this brake 
would be responsible for sending “off” signals that would prevent someone from getting aroused 
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in an inappropriate setting, for example. The second brake is a more chronic and subtle “no thank 
you” signal, associated with the threat or fear of performance failure (Janssen & Bancroft, 2007). 
Arousability is redefined as this two-part process comprised of activating the accelerator and 
deactivating the break, involving a complex coordination between internal and external contexts 
and stimuli.  
 
Rethinking sexual normalcy and dysfunction through the DCM 
The DCM resists sexual essentialism through its recognition of context and variability. 
The model allows for sexual variation between different people and across life stages, as there is 
no one “correct” partnership between accelerator and brakes. SES and SIS are considered traits 
because all bodies possess them, but they vary in sensitivity from person to person. The 
sensitivity of one’s accelerator and brakes is both biological and reliant on life context, which 
incorporates sociocultural, gendered, relational, circumstantial and personal factors. Beyond 
rejecting essentialist models created within a male-dominated paradigm, the DCM also 
encourages the deconstruction of “dysfunction” as it’s currently defined.  
One of the difficulties in accurately quantifying and classifying female sexual desire is 
the inability to arrive at a consensus on how to define and locate it. Desire as discussed in the 
context of the human sexual response cycle is spontaneous and universal. Recall Kaplan’s notion 
of desire as a hunger or a thirst, perpetuating sex as a natural, innate drive rather than a learned 
response. If sexual desire was a drive, like hunger or thirst, then a lack of sexual desire would 
indicate unhealthy or disordered behavior. Therefore unlearning the concept of the sex drive 
negates the interpretation of libido fluctuations as indicators of normal sexual functioning. 
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According to the Dual Control Model, desire is the presence of arousal, which involves 
activating the SES and deactivating the SIS, combined with the right context (Nagoski, 2015). 
Emphasizing the contextual aspect of desire accounts for variability among and within gendered 
groups and views desire not as linear, but rather circular, overlapping, complex and nuanced. 
Desire is an unlocatable process of interactions, rather than a fixed, determined state.  
Context consists of person’s external circumstances and internal brain state in the present 
moment. Nagoski provides the important example of stress as a predictor of sexual interest. 
Stress reduces sexual interest in 80-90% of people and reduces sexual pleasure in basically 
everyone (Nagoski, 2015). Self-criticism and frustration are two forms of stress that can 
significantly affect sexual pleasure (ibid.). Considering that the classification of HSDD and the 
target audience for Addyi revolve around heterosexual, long-term partnerships, relational context 
is of particular importance. Relationship factors are critical in experiencing sexual desire, fantasy 
and arousal (Meana, 2010). An individual’s relationship well-being, along with their own general 
well-being, is the best predictor of distress accompanying low desire, one of the HSDD 
diagnostic criteria and the primary reason people seek treatment (Bancroft, Loftus & Long, 
2003). The Dual Control Model’s emphasis on accounting for context in the assessment of 
sexual difficulty interrogates the role of interpersonal interactions.  
The DCM emphasizes individual uniqueness in sexual response, yet it also notes 
gendered trends in the coordination between SES and SIS. As I previously mentioned, I do not 
intend to promote a strict binary between male and female sexual response. However it is 
important to recognize differences between cisgendered groups in order to deconstruct dominant 
assumptions and omissions regarding female sexuality and encourage a more comprehensive and 
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careful approach to female sexual issues. Women, on average, tend to have more sensitive brakes 
and less sensitive accelerators than their male counterparts. A sensitive brake is the strongest 
predictor of sexual issues, as it correlates with low sexual desire and difficulty with arousal and 
orgasm. Women also tend to have more complications in the overlap between the brain’s 
response and the genital response to sexually relevant stimuli (Nagoski, 2015). This phenomenon 
of “arousal nonconcordance” was the reason why Viagra and testosterone interventions proved 
unable to successfully address low female sexual desire. The differentiation between genital 
response and subjective arousal goes against the standard narrative that often dictates sexual 
expectations. 
The current models of sexual response and classifications of sexual disorders demand 
universal and constant readiness for sexual partnered activity, disregarding the common tendency 
of cisgender women in long-term heterosexual relationships to lose sexual desire with partners 
(Meana, 2010). Key reasons for reduced sexual libido for women in long-term relationships 
include the institution of the relationship, over familiarity between partners, and the 
de-sexualization of roles. This trend, occurring within the specific target audience for potential 
Addyi users, necessitates an incorporation of the relationality of desire to address female sexual 
issues. I am not suggesting that monogamy is inherently detrimental for female sexual desire. 
There is of course variation in this trend, with some relationships working better than others to 
sustain sexual desire. However recognizing and exploring the myriad of factors that contribute to 
low female sexual desire such as relationship dynamics and sexual preferences can direct focus 
to addressing a willingness to feel desire, rather than expectation.  
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A “new view” of sexual issues needs to recognize the influence of context to prompt 
exploration into the sexual scripts which inform and organize our sexual experiences. Sexual 
desire is tied to a gendered social learning process, as we organize our experiences according to 
the sexual scripts we are exposed to. The cultural template by which we learn sexual goals and 
expectations moves us towards or away from certain types of sexual behavior (Nagoski, 2015). 
As a general example, boys tend to learn to associate things that make them aroused with 
erections, while girls link sexually relevant cues to social context and environmental awareness 
due to the less obvious physiological response (ibid.). Interrogating sexual scripts provides 
insight into the societal ambivalence towards female sexuality. We grow up with contradictory 
messages about sex and sexuality that are internalized in our own relationship to sex. It is with 
these sexual scripts that a discrepancy between what women feel and what they think they should 
feel is created. 
 
Addressing female sexual issues within the DCM 
The widespread acceptance of the Dual Control Model would necessitate a reevaluation 
of the dominant classifications of and treatments for female sexual disorders. The DCM 
challenges sexual normalcy, which forms the foundation of sexology. If we acknowledge that 
variation in desire between individuals and life stages is natural and common, it becomes 
difficult to classify low desire as a disorder. Desire as it is viewed under the Dual Control Model 
is subjective, complex, experiential, and interactive, resisting measurement by existing clinical 
indices and tools. The model undermines the biological and essentialist framing of dysfunction 
through highlighting its failure to accommodate for context, such as social or relationship 
O’Bryan 73 
factors. It becomes clear why a drug solution to low female desire is implausible and 
unpromising when pleasure, desire, and arousal are viewed as complex and unique processes, 
rather than fixed states based in one area of the brain or body.  
While the DCM works to shift contemporary perceptions and expectations of sexuality, it 
still acknowledges the importance of finding ways to address female sexual issues without 
resorting to a purely normative framework. Drug interventions such as Addyi focus on the 
biological, without interrogating sociocultural, relational, or individual context. In order to 
understand a woman’s sexual difficulties, questions should be asked regarding the sensitivity and 
triggers of her accelerator and brakes. Nagoski has written worksheets to calculate SES and SIS 
sensitivity, identify stressors and stress management strategies, and assess sexual cues and 
threats, as examples of potential avenues to understand the root of sexual issues. This approach 
necessitates a mindful and self-reflective learning process to ground one’s sexual behavior in the 
situations or cultural expectations that may be a source of distress and low desire. The key to 
leading a satisfying sexual life according to the DCM is to accept your sexual functioning as 
normal, identify the contexts that affect your accelerator and brakes, and develop skills to 
maximize the contexts that increase sexual feelings. You don’t need Addyi to do that. 
 
Final thoughts 
The development of Addyi is contextualized within a long history of medicalizing female 
sexuality, characterized by an increasing emphasis on biologically essentialist frameworks. The 
attempts to design a ‘female Viagra’ proved slow and complicated despite pharmaceutical 
interest and funding, as well as a large estimation of market interest. Addyi was met with 
O’Bryan 74 
institutional and social opposition due to the contentious interactions between corporate interest 
and female sexuality. The drug was sensationalized through Cindy Eckert’s media presence and 
the coverage of competing feminist organizations’ discussions of the role of Big Pharma in 
treating female sexual issues. The response towards Addyi illustrates the cultural ambivalence 
towards female sexuality and the consistent struggle to define, locate, measure, and treat sexual 
behavior that falls outside the lines of “normalcy” as defined by sexology.  
The relationship we have with ourselves and with each other is mediated through the 
production of knowledge and technology. The definitions, classifications, and treatments 
promoted to address sexual issues are rooted in male-dominated norms that uphold sexual 
essentialist approaches to medicalization. The hegemonic model of female sexual response 
demands constant, universal sexual readiness within long-term, heterosexual partnerships. 
Failing to account for sexual diversity has led to a fruitless search for an effective drug to target 
low female sexual desire. Addyi represents the most successful pharmaceutical treatment for 
HSDD introduced thus far, and yet it is fraught with controversy and uninspiring results. Framed 
as a game-changer for female sexual issues, the ‘female Viagra’ was accompanied by high 
barriers to usage, questionable safety, low efficacy, and a feminist countermovement. In order to 
revolutionize female sexuality, we must interrogate the misconceptions that informed 
interventions like Addyi.  
Current medical approaches to address female sexual issues are simply not working. The 
rise of alternative models such as the Dual Control Model undermines the current 
male-dominated paradigm to promote a comprehensive understanding of female sexual response. 
The DCM asserts that diversity in desire is normal and urges individuals to value their sexuality 
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despite the inability to fit into the the standard cultural narrative. Through challenging the 
internalized messages that guide sexual expectations and frustrations, attention is directed at the 
real-life contexts that shape our sexual experiences. We can uphold women’s agency and 
autonomy in sexual research by asking questions beyond the ​what​ to look at the ​why​ and the 
how​. These questions provide a starting point for progressive, women-centered research into the 


















ADDENDUM. THE HUNT CONTINUES  
This past year, the FDA accepted AMAG’s New Drug Application for Vyleesi, or 
bremelanotide, a new pharmaceutical treatment for HSDD. In contrast to Addyi, Vyleesi is taken 
as desired rather than daily, impacting ​neural pathways in the brain ​with only mild to moderate 
side effects (AMAG, 2018). It represents a more efficient Addyi, but does its avoidance of 
Addyi’s high barriers to usage indicate that its a better tool for female empowerment? Will 
Vyleesi be the blockbuster ‘female Viagra’ that developers have been searching for? Does an 
on-demand solution represent a more developed medicalization of female sexuality? Vyleesi 
continues to promote the investment of energy and funding into drug development without 
interrogating the sociocultural values embedded within the technology we produce. This new 
drug may have less safety precautions and higher efficacy rates than Addyi, but it is predicated 
on the same misconceptions and expectations of female sexual desire. It operates, even more 
successfully than Addyi, within the paradigm of Viagra to reinforce conventional standards of 
female sexual normalcy and disempower sexual diversity. I suspect that the drug will not live up 
to its claims, given its reliance on flawed and incomplete understandings of female sexuality. Its 
failure to address low female sexual desire successfully would add a layer to the claims argued in 
this thesis and reinforce the need to direct energy away from pharmaceutical treatment for female 
sexual issues. The drug’s FDA hearing is set to occur within the next several months, and then it 
will be introduced to the market. Vyleesi is estimated by AMAG to have $1 billion in revenue 
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